Nanostructures and uses thereof

By developing spherical nanostructures, the shortcomings of existing nanocarriers in delivering radioisotopes in cancer treatment have been addressed, achieving efficient delivery to tumor tissues and protection of healthy tissues, while reducing production costs.

CN118922213APending Publication Date: 2024-11-08SPAGO NANOMEDICAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380026531.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-08
Filing Date
2023-03-08
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing nanocarriers have limitations in effectively delivering radioactive isotopes to tumor tissues during cancer treatment, particularly due to insufficient penetration and retention effects caused by their large size, and traditional systemic radiotherapy may damage healthy tissues.

Method used

Several spherical nanostructures with volume-average hydrodynamic diameters ranging from 13 nm to 90 nm and low dispersion were developed. These nanostructures, formed by Si-O-Si linked polymer frameworks and coated with hydrophilic coatings, were used to prepare nanocarriers capable of effectively delivering radioisotopes to tumor cells.

Benefits of technology

This technology enables efficient delivery to tumor tissues, reduces damage to healthy tissues, improves the targeting and therapeutic efficacy of radioisotopes, and simultaneously reduces production costs and material losses.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118922213A_ABST
    Figure CN118922213A_ABST
Patent Text Reader

Abstract

The present application relates to a plurality of spherical nanostructures having a dispersion of between 1 and 1.8 and a volume average hydrodynamic diameter of from 13 nm to 90 nm; wherein each nanostructure comprises a polymeric framework of monomer residues, wherein the average number of bonds from each monomer residue is in the range from 3.0 to but not including 6.0; wherein at least 90% of the monomer residues comprise two gem-chelating groups, each chelating group being independently PO (OR1) (OR2); wherein R1 and R2 are independently selected from the group consisting of a negative charge and H; and '-' represents an internal bond in a monomer residue. The invention also relates to a method for producing the nanostructure, a use of the nanostructure and a pharmaceutical composition comprising the nanostructure.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to chelated polymer nanostructures which are used as intermediates for the production of nanostructures for use in systemic radiation therapy and cancer imaging. Background Art

[0002] The gold standard for cancer treatment is surgery. In cases where surgery alone is not curative, multimodal treatment options including chemotherapy and radiation therapy may be used. Currently, approximately half of all cancer patients are treated with radiation therapy, either alone or in combination with other treatments. Radiation delivered as an external beam provides a relatively simple and practical method of inflicting radiation damage to tumors. Although the intensity, location, and timing of external radiation can be well controlled and modulated, disadvantages associated with this technology include destruction of normal tissue in the beam path and damage to tissue surrounding the tumor. The risk of causing damage to surrounding healthy tissue is not conducive to external radiation therapy for tumors located deep in the body and near vital organs. In addition, high radiation doses are often required to penetrate tissue. In addition, in order to be effective, external radiation therapy often requires patients to visit the hospital every day for a long period of time.

[0003] Systemic radiation therapy delivers radioactive material to the tumor from within, offering a solution to many of the above-mentioned disadvantages associated with external radiation therapy.

[0004] Currently, the most commonly used radionuclides for systemic radiotherapy in clinical practice are beta-emitters. The maximum tissue penetration range (1-10 mm) and cross-fire effects (i.e., the ability to indirectly kill cells along a longer path length) of beta-particles with energies between 0.1 and 2.2 MeV make it possible to target tumor cells close to new blood vessels. Radionuclides (e.g. 131 I) can be used alone or in combination with monoclonal antibodies or peptides for tumor-targeted radioimmunotherapy. Clinical applications of α-emitters are less common, with some showing clinical potential, e.g. 223 Ra.

[0005] Recent advances in nanotechnology have led to the development of novel nanocarriers designed for cancer detection and screening, in vivo molecular and cellular imaging, and delivery of therapeutic agents. However, despite the large number of publications on nanocarriers for cancer therapy, relatively few have entered clinical trials and only a few have received FDA approval.

[0006] The fundamental reason why nanosized materials are suitable as tumor-targeted radiation carriers is related to the enhanced permeation and retention (EPR) effect. The EPR effect is based on the fact that the capillaries of healthy tissues are almost impermeable to molecules larger than 3-4nm, while the permeability of capillaries of rapidly growing tumor tissues is much higher. In addition, solid tumors often lack functional lymphatic vessels. Taken together, these characteristics limit the removal of extravasated nanomaterials from most solid tumors, resulting in the accumulation of nanosized materials in tumors. Since EPR-mediated drug targeting completely relies on the pathological properties of the target tissue, namely enhanced leakage and poor lymphatic drainage, it is often referred to as passive tumor targeting.

[0007] EP 2 923 712 A1 discloses nanostructures having a hydrodynamic diameter of 8-100 nm which can be used for imaging and / or radiotherapy.

[0008] US20140004048 describes nanoparticles that have been dendrite-treated to increase the solubility of the nanoparticles.

[0009] Many methods of radioisotope therapy involving such nanocarriers suffer from the following drawbacks: the nanocarriers are not true nanocarriers because they are larger than 100 nm and due to their larger size suffer from the drawback of not being able to deliver radioisotopes to tumor tissue in an effective manner. WO 2004 / 040972 is an example of a carrier larger than 100 nm. Summary of the invention

[0010] According to a first aspect, the above and other objects are fully or at least partially achieved by the composition defined in claim 1. According to this claim, the above objects are achieved by a plurality of spherical nanostructures, wherein the plurality of spherical nanostructures have a dispersity between 1 and 1.8; and wherein the nanostructures have a volume average hydrodynamic diameter of 13 nm to 90 nm and wherein each nanostructure comprises a polymer framework of monomer residues, wherein the average number of bonds from each monomer residue is in the range of 3.0 to but not including 6.0; wherein the linkages between the monomer residues are Si-O-Si; wherein each nanostructure comprises 10 wt% to 25 wt% silicon; wherein at least 90% of the monomer residues have 5 to 11 carbon atoms; wherein at least 90% of the monomer residues comprise two geminal chelating groups, each chelating group being independently a group according to formula (I),

[0011] -PO(OR 1 )(OR 2 )(I)

[0012] Where R 1 and R 2are independently selected from the group consisting of negative charge and H; and "-" represents an internal bond in a monomer residue; and wherein the chelating groups according to formula (I) constitute at least 90% of the chelating groups in the nanostructure.

[0013] The term "two geminal chelating groups" refers to two chelating groups separated by one carbon atom, ie, the two chelating groups are bound to the same carbon atom.

[0014] Importantly, the present application relates to a plurality of spherical nanostructures with defined dispersities. In addition, the spherical nanostructures described herein can be used as the "core" or "center" of a coated nanostructure. A plurality of such coated nanostructures can also have low dispersities. Some newly discovered advantages are related to low dispersities. As shown in Example 6, the optimal size for delivery to a tumor is about 30 nm. Therefore, as long as the average diameter is around 30 nm, the lower the dispersity of the coated nanostructure, the better it is delivered to the tumor. Since the dispersity of the core nanostructure is converted into the dispersity of the coated nanostructure, it is advantageous for a plurality of nanostructures to have low dispersities. In addition, low dispersities provide less loss during the production of the coated nanostructure and therefore provide better economy, because the coated nanostructures beyond the expected range will have to be filtered out.

[0015] As described above, the plurality of spherical nanostructures have a dispersity between 1 and 1.8. The dispersity can be measured by DLS as described in detail below or by other methods known in the art. Nanostructures with such low dispersity are particularly useful for producing coated nanostructures that can be used for in vivo applications such as imaging and radiotherapy.

[0016] The dispersity may be between 1 and 1.5, between 1 and 1.3 or between 1.1 and 1.35, for example less than 1.3.

[0017] The dispersion of the core nanostructure of the plurality of nanostructures according to the present application is converted into the dispersion of the coated nanostructure (described below). Notably, the lower the dispersion of the coated nanostructure, the better the delivery to the tumor.

[0018] The nanostructures may have a volume average hydrodynamic diameter of 13 nm to 90 nm, such as 13 nm to 50 nm, such as 13 nm to 30 nm, such as 14 nm to 25 nm, such as 15 nm to 22 nm, such as 16 nm to 20 nm. Thus, the volume average hydrodynamic diameter may be 17 nm to 19 nm, such as 18 nm.

[0019] The nanostructures according to the present application are small enough to leak through defective capillaries and diffuse through the intracellular matrix to deliver radioactivity to tumor cells.

[0020] The "average number of bonds from each monomer residue" is the average number of bonds of a monomer to the polymer framework, ie to other monomers.

[0021] The polymer network may be amorphous.

[0022] The polymer framework can be a homopolymer of a single monomer, or a copolymer of two or more different monomers, preferably with a random branching and crosslinking pattern. This is in contrast to the ordered branching pattern in, for example, dendron molecules. In the case where the polymer framework is a copolymer, the nanostructure comprises a randomly ordered polymer.

[0023] The average number of bonds per monomer residue may be in the range of 3.5 to 5.9, such as 3.7 to 5.5, such as 4.0 to 5.0, such as 4.5. A greater number of bonds from each monomer residue generally increases storage stability and in vivo stability. In addition, higher crosslinking produces a denser nanostructure, wherein the chelated phosphonate groups (-PO(OR 1 )(OR 2 )) are positioned closer to each other. This is believed to provide greater chelation stability.

[0024] As described above, the nanostructures include 10 wt % to 25 wt % silicon. The weight of silicon refers to the percentage of silicon in a dried sample of the nanostructure. The drying process is as shown in Example 11 below. In some embodiments, the nanostructures include 13 wt % to 18 wt % silicon.

[0025] As stated above, at least 90% of the monomer residues have from 5 to 11 carbon atoms. Preferably, at least 95%, such as at least 99%, of the monomer residues have from 7 to 9 carbon atoms.

[0026] As mentioned above, at least 90% of the monomer residues include two geminal chelating groups according to formula (I) as described above. Preferably, at least 92%, such as at least 95%, such as at least 97%, such as at least 99%, such as 100% of the monomer residues include two chelating groups according to formula (I) as described above.

[0027] The chelating groups according to formula (I) may constitute at least 95%, such as at least 99%, of the chelating groups in the nanostructure.

[0028] The spherical chelated polymer nanostructures according to the present application can be used as intermediates in the production of coated nanostructures for use in radioisotope therapy and cancer diagnosis. In particular, they are suitable as the core of coated nanostructures for use in systemic radiotherapy and cancer imaging.

[0029] The nanostructures according to the present application are bio-inert, since biodegradability would result in an undesirable and uncontrolled loss of radioisotopes from the nanostructures. Such uncontrolled loss of radioisotopes could cause radiation damage to vital organs, such as the liver and kidneys.

[0030] Nanostructures according to the present application can be used as intermediates for preparing nanocarriers or nanomaterials, which are higher than the threshold value of the dye to be excreted by the kidneys and thus cause damage and / or drain from the body. Meanwhile, nanostructures according to the present application and coated nanostructures are small enough (having a diameter lower than 90nm and lower than 100nm, respectively) to be able to leak through defective capillaries and diffuse through the intracellular matrix, delivering radioactivity to tumor cells. Although it is not definite or restrictive in any respect, it is conceivable that the EPR effect is generally the basis for the favorable tumor delivery properties of the material derived from the nanostructure according to the present application.

[0031] According to one embodiment, the dispersion is between 1 and 1.5, such as between 1 and 1.3, such as between 1.1 and 1.35, such as less than 1.3.

[0032] According to one embodiment, at least 90% of the monomer residues incorporated into the polymer framework are residues according to formula (II):

[0033] {(OR 1 )(OR 2 )PO}2-(C){(CH2) n Si(OR 3 )3}{(CH2) n Si(OR 3 )3}(II)

[0034] Each R 1 and R 2 are independently selected from the group consisting of a negative charge and H; each R 3 are independently selected from the group consisting of a negative charge, H, and a covalent bond to a polymer framework; wherein at least 3 R 3 is a bond to the polymer framework; and n is an integer between 1 and 5.

[0035] Since at least three of the R 3 The crosslinks between monomers in the nanostructures of the present application, which are bonds to the polymer framework, are higher than those in which there are less than 3 R 3 The corresponding nanostructures are formed by the bonds of the polymer framework, so the nanostructures have better storage stability and in vivo stability. In addition, higher cross-linking provides a denser nanostructure, in which the chelated phosphonate groups (-PO(OR 1 )(OR 2)) are positioned closer to each other. This is believed to provide greater chelation stability.

[0036] At least 4, for example at least 5, for example 6 R 3 The - group may represent a bond to the polymer framework.

[0037] At least 4 Rs 3 The - group may be a bond to the polymer framework.

[0038] In some embodiments, at least 5, for example 6 R 3 The - group may be a bond to the polymer framework.

[0039] In one embodiment, n is 3. This nanostructure has proven to be particularly effective.

[0040] In one embodiment, at least 3 R 3 The - group is a bond to the polymer framework; and n is 3.

[0041] In one embodiment, at least 4 R 3 The - group is a bond to the polymer framework; and n is 3.

[0042] In one embodiment, at least 5 R 3 The - group is a bond to the polymer framework; and n is 3.

[0043] In one embodiment, all six R 3 The - group is a bond to the polymer framework; and n is 3.

[0044] The nanostructure may further include a coating. The coating contributes to the biocompatibility of the nanostructure.

[0045] Typically, the coated nanostructures as described herein have a volume average hydrodynamic diameter of 18 nm to 100 nm, such as 20 nm to 50 nm, such as 25 nm to 35 nm.

[0046] Preferably, the coating increases the diameter of the nanostructures by at least 5 nm, such as 5 nm to 25 nm, such as 10 nm to 20 nm, such as 15 nm. In other words, the coating has a thickness of at least 2.5 nm, such as 2.5 nm to 12.5 nm, such as 5 nm to 10 nm, such as 7.5 nm.

[0047] The coating contributes to the biocompatibility of the nanostructures.

[0048] Preferably, the coating comprises hydrophilic groups. This imparts water solubility, biocompatibility and aggregation stability.

[0049] Therefore, coating may be a coating of a hydrophilic polymer, for example comprising a coating of polyethylene glycol (PEG), polyoxazoline or peptoids. Preferably, each polyethylene glycol chain comprises 10 to 150 ethylene glycol units, for example 20 to 100 ethylene glycol units, for example 30 to 50 ethylene glycol residues, for example 45 ethylene glycol residues.

[0050] The coating may include residues of coating monomers comprising one or more polyethylene glycol chains and one or more silicon atoms connected via an organic linker. Several ethylene glycol units linked together are also referred to as polyethylene glycol chains or PEG chains.

[0051] Preferably, the coating comprises a coating monomer residue comprising 2 silicon atoms and 2 polyethylene glycol chains, each polyethylene glycol chain comprising 20 to 100 ethylene glycol units.

[0052] Specifically, the coating may include a coating monomer residue comprising one or more polyethylene glycol chains and one or more silicon atoms connected by an organic linker. The organic linker may be a hydrocarbon. The organic linker may also include an ether bond. The silicon atom in the monomer may be present in a reactive siloxane group, such as -Si(OEt)3, -Si(OMe)3 or -SiCl3.

[0053] When the coating includes a coating monomer residue containing a silicon atom, the coating monomer residue is bonded to the remainder of the nanostructure via a siloxane bond.

[0054] The coating can be grafted onto the nanostructures by reaction between the nanostructures and a coating monomer containing reactive siloxane groups (eg, -Si(OEt)3, -Si(OMe)3, or -SiCl3).

[0055] The preferred coating monomer is (m-PEG x OCH2)2C]-CH2CH2CH2-Si(OEt)3], wherein m is an abbreviation for methyl and x is an integer between 10 and 150, such as between 20 and 100, such as between 30 and 50, such as 45 ethylene glycol residues.

[0056] Other preferred coating monomers are m-PEG x -CH2CH2CH2-Si(OEt)3, wherein m is the abbreviation for methyl and x is an integer between 10 and 150, such as between 20 and 100, such as between 30 and 50, such as 45 ethylene glycol residues.

[0057] Other preferred coating monomers are 1-(ω-methyl-(ethyleneoxy) x-methyl)-3,5-bis(3-(triethoxysilyl)propoxy)-benzene, wherein x is an integer between 10 and 150, such as between 20 and 100, such as between 30 and 50, for example 45; and 1,7-bis(triethoxysilyl)-4,4-bis(ω-methyl-(ethyleneoxy) x -methyl)-heptane, wherein x is an integer between 10 and 150, such as between 20 and 100, such as between 30 and 50, for example 45.

[0058] According to a second aspect, a pharmaceutical composition comprising a plurality of spherical nanostructures is disclosed, wherein the spherical nanostructures comprise a coating according to the present application. Preferably, the hydrophilic groups of the coating are as described above.

[0059] The pharmaceutical composition may be in the form of a liquid solution. Preferably, the liquid solution is an aqueous solution. In one embodiment, the aqueous solution has a pH of 3.5 or less.

[0060] The pharmaceutical composition may further comprise a liquid, such as water.

[0061] The pharmaceutical composition may further comprise at least one antioxidant and / or at least one cryoprotectant.

[0062] The spherical nanostructures of the pharmaceutical composition may further include a radioactive isotope. Suitable radioactive isotopes are described below.

[0063] The pharmaceutical composition according to the second aspect may be a pharmaceutical composition for use as a medicament.

[0064] According to a third aspect, a pharmaceutical composition for cancer treatment and / or for imaging is provided, wherein the pharmaceutical composition comprises a plurality of spherical nanostructures, the spherical nanostructures comprising a coating according to the present application, wherein the spherical nanostructures further comprise a radioactive isotope. Preferably, the hydrophilic group of the coating is as described above.

[0065] The imaging may be PET imaging or SPECT imaging.

[0066] The radioisotope may be selected from the group consisting of: actinium-225 ( 225 Ac); copper-62( 62 Cu); Copper-64( 64 Cu); Copper-67( 67 Cu); Gallium-67( 67 Ga); Gallium-68( 68 Ga); Holmium-166( 166 Ho); indium-111( 111 In); Lead-212( 212 Pb); Lutetium-177( 177Lu); radium-223( 223 Ra); rhenium-186( 186 Re); Rhenium-188( 188 Re); Rubidium-82( 82 Rb); Samarium-153( 153 Sm); Strontium-89( 89 Sr); Technetium-99m( 99m Tc 3+ ); Thallium-201( 201 Tl); Thorium-227( 227 Th); Yttrium-86( 86 Y); Yttrium-90( 90 Y) and zirconium-89 ( 89 Zr) and combinations thereof. Thus, two or more radioactive isotopes may be present in a pharmaceutical composition for imaging and / or cancer treatment.

[0067] In particular, the radioisotope used for treatment may be selected from the group consisting of: actinium-225 ( 225 Ac); copper-64( 64 Cu); Copper-67( 67 Cu); Holmium-166( 166 Ho); lead-212( 212 Pb); Lutetium-177( 177 Lu); radium-223( 223 Ra); rhenium-186( 186 Re); Rhenium-188( 188 Re); Samarium-153( 153 Sm); Strontium-89( 89 Sr); Thorium-227( 227 Th) and Yttrium-90 ( 90 Y) and combinations thereof. Therefore, two or more radioactive isotopes may be present in a pharmaceutical composition for cancer treatment.

[0068] In particular, the radioisotope used for imaging may be selected from the group consisting of: copper-62( 62 Cu); Copper-67( 67 Cu); Gallium-67( 67 Ga); Gallium-68( 68 Ga); Indium-111( 111 In); Lutetium-177( 177 Lu); rhenium-186( 186 Re); Rubidium-82( 82 Rb); Technetium-99m( 99m Tc 3+ ); Thallium-201(201 Tl); Yttrium-86( 86 Y) and zirconium-89 ( 89 Zr) and combinations thereof. Thus, two or more radioactive isotopes may be present in the pharmaceutical composition for imaging.

[0069] Radioisotopes suitable for PET imaging may be selected from copper-62( 62 Cu); Gallium-68( 68 Ga); Rubidium-82( 82 Rb); Yttrium-86( 86 Y) and zirconium-89 ( 89 Thus, two or more radioactive isotopes may be present in the pharmaceutical composition for PET imaging.

[0070] Radioisotopes suitable for use in SPECT imaging may be selected from gallium-67( 67 Ga); Indium-111( 111 In); Technetium-99m( 99m Tc 3+ ); Lutetium-177( 177 Lu) and thallium-201( 201 Thus, two or more radioactive isotopes may be present in the pharmaceutical composition for SPECT imaging.

[0071] In one embodiment of the pharmaceutical composition, the nanostructure comprises a coating as described above and at least 90% of the monomer residues in the central part of the nanostructure are residues according to formula (II):

[0072] {(OR 1 )(OR 2 )PO}2-(C){(CH2) n Si(OR 3 )3}{(CH2) n Si(OR 3 )3}(II)

[0073] Each R 1 and R 2 are independently selected from the group consisting of a negative charge and H; each R 3 are independently selected from the group consisting of a negative charge, H, and a covalent bond to a polymer framework; wherein at least 3 R 3 is a bond to the polymer framework; and n is 3. Specifically, at least 4 R 3 The -groups are bonds to the polymer framework.

[0074] Preferably, the coating comprises a coating monomer residue comprising 2 silicon atoms and 2 polyethylene glycol chains, each polyethylene glycol chain comprising 20 to 100 ethylene glycol units.

[0075] According to a fourth aspect, a method for purifying 1,7-bis(triethoxysilyl)-4,4-bis(dimethoxyphosphonate)heptane is provided, the method comprising the following steps: (a) providing a solution of impure 1,7-bis(triethoxysilyl)-4,4-bis(dimethoxyphosphonate)heptane in a polar aprotic solvent; (b) separating the solution of step (a) from insoluble matter; (c) concentrating the solution obtained in step (b) to provide a residue; (d) treating the solution obtained in step (c) with water; (e) separating the solution obtained in step (d) from the insoluble matter; (f) removing water from the solution obtained in step (e); (g) concentrating the dried solution obtained in step (f) to obtain a second residue; (h) subjecting the residue obtained in step (g) to a short-path straight-through vacuum distillation; and (i) collecting the straight-through fractions from step (h), including purified 1,7-bis(triethoxysilyl)-4,4-bis-(dimethoxyphosphonate)heptane.

[0076] The above steps can be performed in the order of (a), (b), (c), (d), (e), (f), (g), (h), and (i).

[0077] The precipitation steps (steps (a) and (d)) are advantageous for removing oligomeric material that may clog the distillation apparatus.

[0078] The aprotic solvent in step (a) may be a nitrile, a ketone, an ester or a polar ether.

[0079] Examples of suitable nitriles are acetonitrile and propionitrile.

[0080] Examples of suitable ketones are acetone and methyl ethyl ketone.

[0081] Examples of suitable esters are ethyl acetate and isopropyl acetate.

[0082] Examples of suitable polar ethers are THF (tetrahydrofuran) and Me-THF (methyl-tetrahydrofuran).

[0083] Specifically, the aprotic solvent in step (a) can be acetonitrile. Impure 1,7-bis(triethoxysilyl)-4,4-bis(dimethoxyphosphonate)heptane can be dissolved in acetonitrile at a concentration between 5% (w / v) and 20% (w / v), such as between 7% (w / v) and 15% (w / v), such as 10% (w / v), where (w / v) means weight / volume.

[0084] Step (b) may be performed by filtration.

[0085] Alternatively, step (b) may be performed by sedimentation and decantation as well as by filtration.

[0086] Step (c) and / or step (g) may be performed by evaporating the solvent.

[0087] The non-polar solvent in step (d) may be a cyclic or non-cyclic hydrocarbon or a hydrocarbon mixture.

[0088] Examples of suitable cyclic hydrocarbons are cyclohexane and cycloheptane.

[0089] Examples of suitable acyclic hydrocarbons are pentane, hexane and heptane.

[0090] The non-polar solvent in step (d) may be heptane. The residue obtained in step (c) may be dissolved in heptane at a concentration of, for example, between 5% (w / v) and 20% (w / v), for example between 7% (w / v) and 15% (w / v), for example 10% (w / v), where (w / v) means weight / volume.

[0091] Step (e) may be performed by filtration.

[0092] Alternatively, step (e) may be performed by sedimentation and decantation.

[0093] Step (f) may be carried out by drying, for example using molecular sieves, for example The molecular sieve is dried to the solution obtained in step (e). In other words, step (f) can be carried out by drying the solution obtained in step (e) over an activated molecular sieve, optionally followed by filtration. The solvent can be removed by evaporation. If a molecular sieve is used in step (f), step (g) can be carried out by separating the molecular sieve and the solution, and then evaporating the solvent.

[0094] Step (h) of short path, pass-through vacuum distillation may include setting the temperature of the heating element to 150° C. to 190° C., such as 160° C. to 180° C., or such as 165° C. to 175° C., and passing the crude product through the apparatus. Low boiling impurities lacking certain structural features (e.g., silane groups) may then be removed and collected as a distillate, and the purified product is retained.

[0095] Step (h) may be performed multiple times until a satisfactory purity is achieved.

[0096] In the optional second step of the short-path straight-through vacuum distillation, the heating element is set to a higher temperature, such as 170°C to 190°C, and the once purified product is passed through the apparatus again. The product is then evaporated and collected as a distillate, and non-volatiles are retained. This second step is advantageous because the production of many silanes (e.g., 1,7-bis-(triethoxysilyl)-4,4-bis-(dimethylphosphonate)-heptane) may involve a platinum-catalyzed hydrosilylation step and may contain unacceptable amounts of platinum residues. They are non-volatile and are removed in the second step.

[0097] In one embodiment of the process, the polar aprotic solvent in step (a) is acetonitrile and the solution in step (a) has a concentration of impure 1,7-bis-(triethoxysilyl)-4,4-bis(dimethoxyphosphonate)heptane in the range of 25 g / l to 250 g / l; and / or the non-polar solvent in step (d) is a lower alkane, and the solution in step (d) has a concentration of the residue obtained in step (c) in the range of 25 g / l to 250 g / l; and / or the short-path straight-through vacuum distillation in step (h) is carried out in a temperature range of 150° C. to 190° C. and a pressure range of 0.1 mbar to 1 mbar.

[0098] Preferably, the solution in step (a) has a concentration of impure 1,7-bis-(triethoxysilyl)-4,4-bis(dimethoxyphosphonate)heptane in the range of 50 g / l to 200 g / l, more preferably 65 g / l to 150 g / l, even more preferably 75 g / l to 125 g / l and most preferably 100 g / l.

[0099] Preferably, the non-polar solvent in step (d) is heptane.

[0100] Preferably, the solution in step (d) has a concentration of the residue obtained in step (c) in the range of 50 g / l to 200 g / l, more preferably 65 g / l to 150 g / l, even more preferably 75 g / l to 125 g / l and most preferably 100 g / l.

[0101] Preferably, the short-path straight-through vacuum distillation in step (h) is carried out in a temperature range of 150 to 190°C, preferably 160 to 180°C and a pressure range of 0.1 mbar to 1 mbar.

[0102] In a specific embodiment of the process, the polar aprotic solvent in step (a) is acetonitrile and the solution in step (a) has an impure 1,7-bis(triethoxysilyl)-4,4-bis(dimethoxyphosphonate)heptane concentration in the range of 75 g / l to 125 g / l; and / or the non-polar solvent in step (d) is heptane and the solution in step (d) has a residue obtained in step (c) in a concentration range of 75 g / l to 125 g / l; and / or the short-path straight-through vacuum distillation in step (h) is carried out in a temperature range of 160° C. to 180° C. and a pressure range of 0.1 mbar to 1 mbar.

[0103] According to a fifth aspect, there is provided use of 1,7-bis(triethoxysilyl)-4,4-bis(dimethoxyphosphonate)heptane purified according to the method of the present application to produce a plurality of spherical nanostructures according to the present application.

[0104] According to a sixth aspect, a method for preparing a plurality of spherical nanostructures according to the present application is provided, comprising the following steps: (a) providing a solution comprising a monomer in a mixture of water and a lower alcohol, wherein the monomer is a monomer according to formula (II):

[0105] {(OR 1 )(OR 2 )PO}2-(C){(CH2) n Si(OR 3 )3}{(CH2) n Si(OR 3 )3}(II)

[0106] Each R 1 and R 2 is independently selected from the group consisting of lower alkyl and aryl; and each R 3 independently selected from the group consisting of lower alkyl and aryl; and n is an integer between 1 and 5; and (b) placing the solution of step (a) at a temperature of 110°C to 160°C for a period of time such that the growth rate of the nanostructure is significantly lower than the initial growth rate.

[0107] Preferably, R 1 and R 2 is a lower alkyl group, for example, a lower alkyl group containing 1 to 8 carbon atoms. More preferably, R 1 and R 2 It is -CH3.

[0108] Preferably, R 3 - group is a lower alkyl group, for example a lower alkyl group containing 1 to 8 carbon atoms. More preferably, R 3 The -group is -CH2-CH3.

[0109] Preferably, n=3.

[0110] In a specific preferred embodiment, R 1 and R 2 is -CH3; R 3 The -group is -CH2-CH3, and n=3.

[0111] In step (b) the temperature may be between 115°C and 145°C, for example between 125°C and 140°C.

[0112] In step (b), the time period may be between 30 hours and 300 hours, such as between 40 hours and 250 hours, such as between 45 hours and 225 hours, such as between 48 hours and 200 hours. In some cases, the time period may be even shorter, such as 25 hours, 20 hours, 15 hours, 10 hours or 5 hours.

[0113] In a preferred embodiment, in step (b), the period of time is between 45 hours and 50 hours.

[0114] Preferably, in step (b), the solution of step (a) is subjected to a temperature of 125°C for 200 hours or to a temperature of 140°C for 48 hours.

[0115] Preferably, in step (b), the temperature is 140° C. and the heating time is 45 to 50 hours.

[0116] In one embodiment, the monomer concentration is 20 mM to 85 mM, such as 30 mM to 80 mM, such as 35 mM to 75 mM, such as 40 mM to 70 mM, such as 45 mM to 65 mM.

[0117] In another embodiment, the monomer concentration is 30 mM to 85 mM, such as 35 mM to 80 mM, such as 40 mM to 75 mM, such as 45 mM to 70 mM, such as 50 mM to 65 mM.

[0118] In another embodiment, the monomer concentration is 35 mM to 85 mM.

[0119] In one embodiment, the monomer concentration is 20mM to 85mM, such as 30mM to 80mM, such as 35mM to 75mM, such as 40mM to 70mM, and the reflux temperature is 140° C. or higher. Preferably, in this embodiment, the reaction time is 40 hours to 140 hours, such as 40 hours to 120 hours, such as 40 hours to 100 hours, such as 40 hours to 80 hours, such as 40 hours to 60 hours, such as 40 hours to 55 hours, preferably 45 hours to 50 hours.

[0120] In another embodiment, the monomer concentration is 30mM to 85mM, such as 35mM to 80mM, such as 40mM to 75mM, such as 45mM to 70mM, and the reflux temperature is 125° C. or higher. Preferably, in this embodiment, the reaction time is more than 250 hours, such as more than 300 hours, such as more than 400 hours.

[0121] Optionally, the method further comprises the step (c) of cooling the solution of step (b) to ambient temperature.

[0122] Optionally, the method comprises a first step of purifying the monomer according to the method of the present application.

[0123] Preferably, the purity of the monomer exceeds 80%, more preferably exceeds 85%, more preferably exceeds 90%, even more preferably exceeds 95%, and in particular exceeds 96%. In this case, the size of the produced nanostructures remains stable at a given size. When this stability is reached, the degree of crosslinking is the highest and the phosphonate is essentially completely hydrolyzed or hydrolyzed to a large extent. In addition, the use of monomers of this purity allows the produced nanostructures to have a narrower size distribution.

[0124] The monomer may be 1,7-bis(triethoxysilyl)-4,4-bis(dimethoxyphosphonate)heptane, preferably purified according to the method of the present application.

[0125] The mixture of water and lower alcohol can be a lower alcohol (lower alcohol having 1 to 8 carbon atoms), with water in a proportion of 5% to 50% (vol / vol), preferably 5% to 25% (vol / vol), for example 5% to 22% (vol / vol), for example 6% to 20% (vol / vol), for example 7% to 18% (vol / vol), for example 8% to 15% (vol / vol), for example 9% to 12% (vol / vol), for example a mixture of 10% to 11% (vol / vol), (vol / vol) indicating volume / volume.

[0126] Preferably, the lower alcohol is selected from the group consisting of ethanol, 1-propanol, 2-propanol or 1,2-propylene glycol, 1,3-propylene glycol and ethylene glycol or a mixture thereof.

[0127] A suitable solvent mixture is water / ethylene glycol in a suitable ratio, such as 50% to 95% ethylene glycol or 80% to 95% ethylene glycol or 88% to 92% ethylene glycol, i.e. the ratio of water in the ethylene glycol is 5% to 50% (vol / vol), such as 5% to 20% (vol / vol), such as 8 to 12% (vol / vol).

[0128] The heating may be carried out in a closed, pressure-resistant container or by reflux at atmospheric pressure.

[0129] The temperature in step (b) may be from 115°C to 145°C, such as from 120°C to 145°C, such as from 125°C to 145°C, such as from 130°C to 145°C, such as from 135°C to 145°C, or such as 140°C.

[0130] The shortest time period in step (b) depends on the temperature, for example a temperature of 125° C. requires a heating time period of 195 hours or more, while a temperature of 140° C. requires a heating time period of 48 hours or more. Preferably, a time period longer than the shortest time period is used.

[0131] Preferably, the heating time is 46 hours to 49 hours, such as 47 hours to 48 hours.

[0132] The prepared nanostructures may be coated, preferably with a coating comprising hydrophilic groups.

[0133] The advantage of this approach is that a subsequent step of chromatographic purification of the prepared nanostructures is usually not required.

[0134] The solution provided in step (a) can be provided by dissolving a monomer having a purity of more than 80% in a mixture of water and a lower alcohol. Preferably, the purity of the monomer is above 85%, or above 90%, or above 95%, or above 96%. Preferably, the monomer is 1,7-bis(triethoxysilyl)-4,4-bis(dimethoxyphosphonate)heptane, preferably purified as described herein.

[0135] The lower alcohol may be an alcohol comprising 1 to 8 carbon atoms. Preferably, the alcohol is ethylene glycol.

[0136] Preferably, R 1 and R 2 is a lower alkyl group, for example comprising 1 to 8 carbon atoms. More preferably, R 1 and R 2 It is -CH3.

[0137] Preferably, R 3 - group is a lower alkyl group, for example comprising 1 to 8 carbon atoms. More preferably, R 3 The -group is -CH2-CH3.

[0138] Preferably, n=3.

[0139] Preferably, R 1 and R 2 is -CH3 and R 3 The -group is -CH2-CH3.

[0140] In a specific preferred embodiment, R 1 and R2 -CH3, R 3 The -group is -CH2-CH3, and n=3.

[0141] Therefore, preferably, the monomer is 1,7-bis-(triethoxysilyl)-4,4-bis-(dimethylphosphonate)-heptane with a purity exceeding 90%, which is optionally purified by the method of the present application.

[0142] Thus, preferably, the monomer in step (a) is 1,7-bis-(triethoxysilyl)-4,4-bis-(dimethylphosphonate)-heptane with a purity of more than 90%, wherein the monomer concentration is 30mM to 40mM, the solvent mixture is 10% water in ethylene glycol, and, in step (b), the temperature is 140°C and the heating time is 45 hours to 50 hours. Preferably, the heating time is 46 hours to 49 hours, such as 47 hours to 48 hours.

[0143] Optionally, 1,7-bis-(triethoxysilyl)-4,4-bis-(dimethylphosphonate)-heptane is purified according to the method of the present application.

[0144] The heating time may be 46 hours to 49 hours, for example 47 hours to 48 hours.

[0145] According to a seventh aspect, there is provided use of a plurality of spherical nanostructures according to the present application and / or a product of the method according to the present application as an intermediate in the preparation of a plurality of spherical coated nanostructures.

[0146] According to an eighth aspect, there is provided a use of a plurality of spherical nanostructures according to the present application and / or a product of a method according to the present application as an intermediate in the preparation of a pharmaceutical product. Preferably, the spherical nanostructures include a coating. Preferably, the coating includes a hydrophilic group. Preferably, the coating is as described above.

[0147] According to a ninth aspect, there is provided use of the pharmaceutical composition of the present application as a carrier of a radioactive isotope, wherein the pharmaceutical composition comprises a plurality of spherical nanostructures, and the spherical nanostructures comprise a coating, preferably wherein the coating comprises a hydrophilic group.

[0148] Other purposes, features and advantages of the present application will be apparent from the following detailed description, experimental data and the appended claims. It should be noted that the present application relates to all possible feature combinations.

[0149] In general, all terms used in the claims should be interpreted according to their ordinary meaning in the technical field unless otherwise explicitly defined herein. Unless otherwise explicitly stated, all references to "a / an / the [component, method, step, etc.]" should be openly interpreted as referring to at least one instance of the component, method, step, etc. Unless explicitly stated, the steps of any method disclosed herein do not have to be performed in the exact order disclosed.

[0150] As used herein, the term "comprises" and variations of this term are not intended to exclude other additives, components, integers or steps.

[0151] Definition of terms

[0152] The term "nanostructure" as used herein relates to entities with overall dimensions in the nanometer range, ie up to 100 nm. The term as used herein does not include structures commonly referred to as "core-shell nanoparticles" or simply "nanoparticles" which usually have an inorganic core and an organic coating.

[0153] As used herein, the term "spherical" is intended to describe a shape in which the minor axis is not less than half the major axis, i.e., the longest axis passing through the center (center of gravity) of the structure is no longer than twice the length of the shortest axis passing through the same point. For purposes of illustration, and not limitation, see Figure 1 .

[0154] As used herein, the term "spherical nanostructure" refers to a nanostructure having a generally spherical form or shape as discussed above. This means that shapes such as sheets, rods, tubes, toroids, chains and ribbons are not included.

[0155] As used herein, the term "hydrodynamic diameter" refers to the diameter of a hypothetical hard sphere that diffuses at the same speed as the nanostructure in a solution, i.e., the diameter of an equivalent hard sphere calculated by the diffusion coefficient according to the Stokes-Einsteins Equation. The term is also referred to as "Stokes diameter" or "Stokes-Einstein diameter". The behavior of the sphere includes hydration and shape. The diffusion coefficient is calculated from time-dependent light scattering data obtained, for example, by dynamic light scattering (DLS) technology. Other technical methods for measuring the diffusion coefficient of nanostructures are known to those skilled in the art and can be used instead. In these cases, the measurement requires citing DLS-measurements. As a comparison, bovine serum albumin measured in aqueous saline (150mM NaCl) with DLS at pH 7 and room temperature has a hydrodynamic diameter of 6.9nm. Depending on whether the number average, volume average or scattering intensity average is used, the calculated values ​​may be slightly different. The volume average is usually the most useful because it shows the nanostructure size of most materials. The average diameter referred to herein refers to the volume average measured at 25°C in normal saline solution or 8% (v / v) ethylene glycol in normal saline.

[0156] The term "DLS" as used herein is an abbreviation for Dynamic Light Scattering (a particle size determination method), and may also be referred to as photon correlation spectroscopy or quasi-elastic light scattering. If not otherwise specified, a given DLS size described in the context and claims refers to the average value of the volume-weighted peak of a sample measured in an aqueous solution (also referred to as saline) with an ionic strength corresponding to 150 mM NaCl or in saline with 8% ethylene glycol (v / v) at 25°C. In other words, the hydrodynamic diameter specified herein refers to the average value of the volume-weighted peak of a sample measured by DLS at 25°C in an aqueous solution (also referred to as saline) with an ionic strength corresponding to 150 mM NaCl or in saline with 8% (v / v) ethylene glycol.

[0157] As used herein, SEC-ELSD is an abbreviation for Size Exclusion Chromatography with Evaporative Light Scattering Detection.

[0158] As used herein, HPLC-ELSD is an abbreviation for High Pressure Liquid Chromatography with Evaporative Light Scattering Detection.

[0159] The term "AFM" as used herein is an abbreviation for atomic force microscope.

[0160] As used herein, the term "ICP-OES" is an abbreviation for Inductively Coupled Plasma - Optical Emission Spectroscopy. ICP-OES is a technique used to determine the elemental composition of a sample.

[0161] A "monomer" is a molecule that can covalently bind to other molecules of the same (and optionally, other classes) to form a polymer (ie, a macromolecule composed of several monomer residues).

[0162] The term "monomer residue" refers to atoms derived from one monomer unit that is incorporated into a larger polymer. Depending on how the monomers are linked, all atoms may be retained, or some atoms may be lost in bonding.

[0163] "Crosslinking" refers to the connection between two different chains in a polymer. It is usually formed by the reaction of a multifunctional monomer (i.e., a crosslinking agent) added when forming the polymer. Crosslinking can also be introduced, for example, by radiation treatment, chemical means or heating. For the materials of the present application, they are network polymers of monomers with multiple branching capabilities, and thus the usual description of the degree of crosslinking becomes somewhat inappropriate. For simplicity, only the average number of bonds between monomers is described herein. For example: if a monomer has the potential to form 6 bonds with other molecules and an average of 3 have been formed, we avoid using the term "degree of crosslinking" and state "an average of 3 bonds bonded to other monomers", or sometimes "an average of 3 bonds bonded to other monomers out of 6 possible bonds".

[0164] The term "cross-linked" refers to a structure formed after forming at least one cross-link.

[0165] A "branch point" is a location in a network polymer where a polymer chain branches into two or more branches.

[0166] As used herein, the term "polymer framework" refers to a group of atoms covalently bonded to form a network structure having multiple crosslinks. The polymer framework is formed by covalently linking suitable monomers and / or oligomers (i.e., a molecular complex consisting of several monomer residues). Some examples of monomers are styrene, propylene, ethylene, tetrafluoroethylene, trifluoroethylene, difluoroethylene, methyl acrylate, ethyl acrylate, hydroxyethyl acrylate, acrylamide, methyl methacrylate, ethyl methacrylate, hydroxyethyl methacrylate, H2N-(CH2) p -COOH (where p is 1 to 10), 3-aminobenzoic acid, 4-aminobenzoic acid, N-vinylpyrrolidone, and silicone precursors such as (CH3COO)2Si(CH3)2. Some examples of polymer frameworks are formed from paired monomers such as terephthalic acid + 1,4-diaminobenzene, terephthalic acid + ethylene glycol, and HCOO-(CH2) p COOH+H2N(CH2) q-NH2 (wherein p and q are independently 1 to 10). Oligomers having 2 to 10 monomer units connected can be used as precursors. Some examples of oligomers having connecting groups different from the above monomers are cyclic silanes or polycyclic silanes, such as hexamethylcyclotrisiloxane, 2,4,6,8-tetramethylcyclotetrasiloxane and decamethylcyclopentasiloxane. Some examples of crosslinking agents are N,N'-methylenebis(acrylamide), O,O'-methylenebis(acrylic acid), epichlorohydrin, divinylbenzene, 1,3-divinyl-tetramethyldisiloxane, 1,3-phenylene diisocyanate, 3,3"-biphenyltetracarboxylic dianhydride, 1,4-butanediol divinyl ether, tetraethoxysilane, oligomeric silicates (e.g., metasilicates), or silsesquioxanes, organosilanes (e.g., bis(triethoxysilyl)methane, bis(triethoxysilyl)ethane, bis(triethoxysilyl)butane, methyltriethoxysilane, ethyltriethoxysilane, and propyltriethoxysilane).

[0167] The polymer framework constitutes the backbone of the nanostructure according to the present application. The nanostructure can be coated as described herein and in this case, the polymer framework constitutes the central portion of the coated nanostructure. Those skilled in the art recognize that the random nature of the polymerization process makes the material a mixture of many similar but in most cases non-identical branching patterns, cross-linking positions and molecular weights.

[0168] The term "chelating group" refers to a chemical group that has the ability to successfully compete with water in the electrostatic binding of positively charged ions. A single chelating group cannot bind very strongly, but if several chelating groups surround a positively charged ion, a synergistically enhanced binding occurs. This is called chelation.

[0169] The expression "arranged in a manner that allows chelation" means that a number of chelating groups as defined above are arranged so that a synergistic enhancement of the binding of positively charged ions can occur. This can be obtained by any statistical method; when a large number of chelating groups are incorporated into a random polymer at such a density that at least several groups are close to each other and can bind the same positively charged ion; or by incorporating preformed units in which the chelating groups are already in close proximity. An example of the latter is the well-known chelating agent DOTA (dodecanetetraacetic acid).

[0170] As used herein, the terms "covalently attached," "covalently linked," and "covalently bound" are synonymous and their meanings are well known to those skilled in the art.

[0171] As used herein, the term "independently selected from" means that each of the different ingredients mentioned before the term is selected from the group following the term independently and separately from the selection of the other mentioned ingredients.

[0172] The term "geminal bisphosphonate group" refers to two phosphonate groups separated by one carbon atom, i.e., the phosphonate groups are bound to the same carbon atom. Compounds comprising geminal bisphosphonate groups are often referred to as 1,1-bisphosphonates (or 1,1-bisphosphonates). The phosphonate groups in the geminal bisphosphonate groups may be substituted.

[0173] The term "radionuclide" refers to an unstable form of a chemical element that undergoes radioactive decay, emitting alpha, beta and / or gamma radiation.

[0174] As used herein, the expression "radionuclide for imaging and / or radiotherapy" refers to actinium-225 ( 225 Ac); copper-62( 62 Cu); Copper-64( 64 Cu); Copper-67( 67 Cu); Gallium-67( 67 Ga); Gallium-68( 68 Ga); Holmium-166( 166 Ho); indium-111( 111 In); Lead-212( 212 Pb); Lutetium-177( 177 Lu); radium-223( 223 Ra); rhenium-186( 186 Re); Rhenium-188( 188 Re); Rubidium-82( 82 Rb); Samarium-153( 153 Sm); Strontium-89( 89 Sr); Technetium-99m( 99m Tc 3+ ); Thallium-201( 201 Tl); Thorium-227( 227 Th); Yttrium-86( 86 Y); Yttrium-90( 90 Y) and zirconium-89 ( 89 The expression "radionuclide for imaging and / or radiotherapy" also covers combinations of two or more of the abovementioned radionuclides.

[0175] As used herein, the expression "radionuclide for imaging" refers to copper-62( 62 Cu); Copper-67( 67 Cu); Gallium-67( 67 Ga); Gallium-68( 68 Ga); Indium-111( 111 In); Lutetium-177( 177 Lu); rhenium-186( 186 Re); Rubidium-82( 82Rb); Technetium-99m( 99m Tc 3+ ); Thallium-201( 201 Tl); Yttrium-86( 86 Y) and zirconium-89 ( 89 The expression "radionuclide used for imaging" also covers combinations of two or more of the abovementioned radionuclides.

[0176] As used herein, the expression "radionuclide for PET imaging" refers to copper-62( 62 Cu); Gallium-68( 68 Ga); Rubidium-82( 82 Rb); Yttrium-86( 86 Y) and zirconium-89 ( 89 The expression "radionuclide for PET imaging" also covers combinations of two or more of the abovementioned radionuclides.

[0177] As used herein, the expression "radionuclide for SPECT imaging" refers to gallium-67 ( 67 Ga); Indium-111( 111 In); Technetium-99m( 99m Tc 3+ ); Lutetium-177( 177 Lu) and thallium-201( 201 T1). The expression "radionuclide for SPECT imaging" also covers combinations of two or more of the abovementioned radionuclides.

[0178] As used herein, the expression "radionuclide used in radiation therapy" refers to actinium-225 ( 225 Ac); copper-64( 64 Cu); Copper-67( 67 Cu); Holmium-166( 166 Ho); lead-212( 212 Pb); Lutetium-177( 177 Lu); radium-223( 223 Ra); rhenium-186( 186 Re); Rhenium-188( 188 Re); Samarium-153( 153 Sm); Strontium-89( 89 Sr); Thorium-227( 227 Th) and Yttrium-90 ( 90 Y) The expression "radionuclide for use in radiotherapy" also covers combinations of two or more of the abovementioned radionuclides.

[0179] As used herein, the expression "radionuclide for PET imaging and radiotherapy" refers to actinium-225 ( 225 Ac); copper-62( 62 Cu); Copper-64( 64 Cu); Copper-67( 67 Cu); Gallium-68( 68 Ga); Holmium-166( 166 Ho); lead-212( 212 Pb); Lutetium-177( 177 Lu); radium-223( 223 Ra); rhenium-186( 186 Re); Rhenium-188( 188 Re); Rubidium-82( 82 Rb); Samarium-153( 153 Sm); Strontium-89( 89 Sr); Thorium-227( 227 Th); Yttrium-90( 90 Y) and zirconium-89 ( 89 The expression "radionuclide for PET imaging and radiotherapy" also covers combinations of two or more of the abovementioned radionuclides.

[0180] As used herein, the expression "radionuclide for SPECT imaging and radiotherapy" refers to actinium-225 ( 225 Ac); copper-64( 64 Cu); Copper-67( 67 Cu); Gallium-67( 67 Ga); Holmium-166( 166 Ho); indium-111( 111 In); Lead-212( 212 Pb); Lutetium-177( 177 Lu); radium-223( 223 Ra); rhenium-186( 186 Re); Rhenium-188( 188 Re); Samarium-153( 153 Sm); Strontium-89( 89 Sr); Technetium-99m( 99m Tc 3+ ); Thallium-201( 201 Tl); Thorium-227( 227 Th) and Yttrium-90 ( 90 Y) The expression "radionuclide for SPECT imaging and radiotherapy" also covers combinations of two or more of the abovementioned radionuclides.

[0181] As used herein, the term "bioinert" refers to a material that is biocompatible, ie, non-toxic to mammals and mammalian cells, and at the same time stable to in vivo degradation (less than 10% degradation) in the human body over a period of one week or more.

[0182] As used herein, the term "oxysilane" refers to any compound having one or more oxygen atoms attached to a silicon atom. Non-limiting examples thereof are:

[0183]

[0184] As used herein, the term "organosilane" refers to an organic compound containing one or more carbon-silicon bonds.

[0185] As used herein, the term "alkoxysilane" refers to any compound having one or more carbon-oxygen-silicon moieties.

[0186] As used herein, the terms "siloxane bond," "siloxane connection," and "siloxane network" refer to a moiety including Si-O-Si.

[0187] The terms "hydrocarbon" and "hydrocarbon chain" are used herein to refer to an organic residue consisting of hydrogen and carbon. The hydrocarbon may be fully saturated or it may include one or more unsaturations. The hydrocarbon according to the present application may contain any number of carbon atoms between 1 and 50.

[0188] As used herein, the term "alkyl" refers to a straight or branched, fully saturated (no double or triple bonds) hydrocarbon group. In this article, the alkyl group can have 1-15 carbon atoms. Typical alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, etc.

[0189] The term "lower alkyl" as used herein refers to an alkyl group having 1 to 8 carbon atoms.

[0190] The term "lower alcohol" as used herein refers to an alcohol having 1 to 8 carbon atoms.

[0191] As used herein, the term "low boiling alcohol" refers to an alcohol having a boiling point below 160°C.

[0192] As used herein, the term "lower alkane" refers to a straight or branched, fully saturated (no double or triple bonds) hydrocarbon having 1 to 8 carbon atoms. When the term is used for a solvent, it refers to a straight or branched, fully saturated (no double or triple bonds) hydrocarbon having 4 to 8 carbon atoms.

[0193] Numerical range: Whenever used herein, unless otherwise indicated, a numerical range such as "1 to 8" or "1-8" refers to each integer within the given range; for example, "1 to 8 carbon atoms" and "1-8 carbon atoms" mean that the alkyl group can be composed of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 8 carbon atoms. However, there are some obvious exceptions to this for those skilled in the art. Specifically, herein, whenever a range is given for a molar ratio (e.g., Si / P molar ratio in a nanostructure), a diameter or size, pH, a period of time, a concentration, an osmotic pressure, or a temperature, the range also includes all decimal numbers falling within the range, including the upper and lower limits.

[0194] As used herein, the term "alkoxy" refers to the formula -OR, wherein R is a lower alkyl group, such as methoxy, ethoxy, n-propoxy, 1-methylethoxy (isopropoxy), n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentoxy, isopentoxy, etc. Optionally, the alkoxy group according to the present application may be substituted.

[0195] As used herein, the term "aryl" refers to a carbocyclic ring (i.e., all carbon) or two or more fused rings (i.e., rings sharing two adjacent carbon atoms) with a completely delocalized π-electron system. Examples of aryl include, but are not limited to, benzene, naphthalene and azulene. Aryl groups according to the application may be optionally substituted, for example, phenoxy, naphthoxy, azuleneoxy, anthraceneoxy, naphthylthio, phenylthio, etc. Aryloxy may be optionally substituted.

[0196] As used herein, the term "conjugate" refers to a molecular entity that is a fluorescent marker, a dye, a spin marker, a radiolabel, a peptide, a ligand for a biological receptor, a chelate, an enzyme inhibitor, an enzyme substrate, an antibody, or an antibody-related structure.

[0197] The term "coated nanostructure" (or nanostructure with a coating) is used to describe a material that can be produced from the nanostructure of the present application by adding one or more layers of additional materials. Such coated nanostructures are typically used in radioisotope therapy.

[0198] As used herein, the term "coating" refers to a layer of material applied to a surface to impart one or more properties to the surface. Typically, the coating is covalently attached to the surface. Typically, the surface is a nanostructured surface. Typically, the properties imparted to the surface include inertness, such as biological inertness. The term "coating" may also refer to the process of applying a coating to a surface, and the term "coat" may be used as a verb, meaning "to apply a coating." It is generally clear to a person skilled in the art which form of the word "coating" is being used at a particular moment.

[0199] The term "dispersity" is used where the term polydispersity was used previously. For most applications, it is important to have a size distribution that is as narrow as possible around the mean, i.e. a low dispersity. For a sample that is perfectly uniform in size, the dispersity is 1, for an inhomogeneous sample the dispersity will be greater than 1. Dispersity can be calculated in different ways, M w / M n or similar M v / M n The ratio of M w is the weight average molecular weight, M n is the number average molecular weight, M v is the volume average molecular weight. Here, we define the dispersity by analogy For nanostructured samples, where d v is the volume mean diameter measured by DLS, d n is the number average diameter measured by DLS, which is recommended by the International Union of Pure and Applied Chemistry (Pure Appl. Chem., Vol. 81, No. 2, pp. 351-353, 2009. doi: 10.1351 / PAC-REC-08-05-02). Another way to describe the dispersion of a material is by comparison with a known size reference. As non-limiting examples given herein as explanations, suitable size references may be bovine serum albumin (BSA) or thyroglobulin or empty cowpea mosaic virus (CPMV) VLPs.

[0200] As used herein, the term "molecular weight" refers to the molecular weight of a compound having a specific molecular structure or the weight average molecular weight (also referred to as mass average molar mass or weight average molar mass) of a compound including a polymer portion, wherein the number of monomers in the polymer portion varies between different individual molecules. Therefore, the molecular weight of a compound having a specific molecular structure is a molecular weight calculated based on the number and type of atoms of the compound or measured by, for example, mass spectrometry. The molecular weight of a compound including a polymer portion refers to a weight average molecular weight, also referred to as mass average molar mass or weight average molar mass, which can be determined by, for example, gel filtration or size exclusion chromatography (SEC). More specifically, the weight average molecular weight can be determined according to ISO 16014-1: 2019 and ISO 16014-5: 2019 ("Using size exclusion chromatography to determine the average molecular weight and molecular weight distribution of polymers"), or according to ISO 16014-1: 2019 in combination with any one of ISO 16014-2: 2019 to ISO 16014-4: 2019. Alternatively, the weight average molecular weight can be determined by SEC and verified using liquid chromatography-mass spectrometry (LC-MS) or high performance liquid chromatography (HPLC).

[0201] As used herein, the term "growth rate" or "rate of growth" refers to the first derivative of the size of a nanostructure with respect to time. For convenience, the rate of growth is usually approximately expressed as the change in size of the nanostructure between two measurements, such as the change in the average hydrodynamic diameter Δd, divided by the time Δt between the two measurements. The size of the nanostructure can be determined by any of many methods known to those skilled in the art (e.g., DLS or SEC). The unit of measurement of the growth rate will depend on the method used to determine the size, but units such as nm / h (if DLS is used for size determination) or minutes / hour (if SEC is used for size determination) can be used.

[0202] The term "resin" as used herein is defined as an insoluble organic material.

[0203] As used herein, the term "(Tris)" refers to tris(hydroxymethyl)aminomethane.

[0204] The term "(w / w)" as used herein means weight / weight.

[0205] The term "(w / v)" as used herein means weight / volume.

[0206] The terms "vol / vol" or "v / v" as used herein mean volume / volume. BRIEF DESCRIPTION OF THE DRAWINGS

[0207] By way of example, embodiments of the present teachings are now described with reference to the accompanying drawings, in which:

[0208] Figure 1 An illustrative illustration of a spherical shape.

[0209] Figure 2 Schematic representation of how chelating groups (denoted by "U") are distributed in a network polymer (denoted by the thick black curve) to form ion binding sites of various binding strengths.

[0210] Figure 3 The nanostructures after long boiling (upper trace) and short boiling (lower trace) are shown. 1 H NMR spectrum.

[0211] Figure 4 The nanostructures after long boiling and short boiling are shown. 31P NMR spectra (from bottom to top: 1H-decoupling after short boil, no 1H-decoupling after short boil, 1H-decoupling after long boil, no 1H-decoupling after long boil) showing how the phosphonate present in the short boil nanostructures (two lower traces) is hydrolyzed to form only one phosphonate peak in the long boil nanostructures (two upper traces).

[0212] Figure 5 Shown are HPLC chromatograms of A) crude 7-bis-(triethoxysilyl)-4,4-bis-(dimethylphosphonate)-heptane with a purity of 54% and B) purified 7-bis-(triethoxysilyl)-4,4-bis-(dimethylphosphonate)-heptane with a purity of 97%, C) detailed information from A and B overlaid to show relative amounts, with crude material as a thin line and purified material as a thick line.

[0213] Figure 6 The SEC chromatogram of the nanostructures prepared according to Example 1B is shown. The average size (average diameter) of the nanostructures is 18.2 nm. The retention time (tR) is in minutes. The three light grey peaks are CPMV (t R ~8.28 minutes), Thyro(t R ~9.04 min) and BSA (t R ~10.05 minutes).

[0214] Figure 7 : is an AFM image of a nanostructure prepared according to Example 1B. The individual nanostructures meet the spherical shape definition. Some aggregates of nanostructures are also visible.

[0215] Figure 8 is a schematic diagram of a production method for producing a nanostructure according to the present application. DETAILED DESCRIPTION

[0216] The present application relates to a spherical nanostructure, a method for purifying a monomer used to produce the nanostructure, a method for producing the nanostructure, and specific uses of the nanostructure.

[0217] Specific aspects and implementations of the present application will be described in detail below.

[0218] Spherical nanostructures

[0219] A plurality of spherical nanostructures according to the present application can be characterized by an average hydrodynamic diameter and a dispersion. Other information measures may relate to average molecular weight and density. The molecular weight of a given spherical nanostructure can be calculated as the product of the nanostructure volume and density calculated according to geometric formulas known in the art.

[0220] The range of sizes of the nanostructures according to the present application is limited by their ability to chelate radioisotopes with high affinity and bind them for many days after administration to a living organism. Example 4 below shows the correlation between the size of the nanostructures according to the present application and their chelation strength. The chelation strength is believed to be sufficient for diameter sizes above 13 nm, particularly sizes above 15 nm.

[0221] The upper size limit is set to have the ability of the coated nanostructures derived from the spherical nanostructures according to the present application to penetrate from the bloodstream to the tumor tissue in the body of the organism. It has been found that due to the high diffusion resistance in the tissue, it is more advantageous to use spherical nanostructures as precursors for coated nanostructures at the lower end of the feasible size range, such as between 13nm and 25nm in diameter, such as between 16nm and 20nm. The diffusion resistance depends on the size of the nanostructure, and for entities with a diameter of more than 100nm, the diffusion resistance has been found to be very high, so that the dose delivered locally to the tumor is too small to be used for many clinical purposes.

[0222] When used for imaging or treatment, the nanostructure preferably includes a coating as described herein. The biodistribution of the coated nanostructure according to the application has been studied (Example 6). The data shown in Example 6 show that the coated nanostructure of about 30nm in diameter has an optimal size. It is estimated that the size of the coated nanostructure should be no more than 100nm, preferably less than 90nm, more preferably less than 60nm, even more preferably less than 35nm. The coating increases the diameter by at least 5nm to 10nm, so the upper limit of the core nanostructure (uncoated nanostructure) of the application is 90nm. Therefore, the nanostructure according to the present invention is less than 90nm, for example, less than 70nm, for example, less than 50nm, for example, less than 30nm, for example, less than 25nm, for example, less than 22nm, for example, less than 20nm.

[0223] In one embodiment, the plurality of nanostructures of the present application having an average size (diameter) of 18 nm have a ratio between protein BSA and virus-like particles CPMV of 95% when measured by SEC-ELSD.

[0224] Example 7 and Figure 7 A plurality of nanostructures of the present application are described with an average size (diameter) of 18.2 nm according to DLS, having a peak area of ​​1.6% in the SEC-ELSD chromatogram and a size higher than the reference CPMV and 2.8% lower than the reference BSA.

[0225] Example 1 describes how to select conditions to produce the nanostructures of the present application within a given size range.

[0226] The nanostructure of the present invention comprises a polymer framework of monomer residues, wherein at least 90% of the monomer residues comprise two geminal chelating groups, each chelating group being independently selected from the group consisting of: -PO(OR 1 )(OR 2 ) group, wherein R 1 and R 2 are independently selected from the group consisting of a negative charge and H; and "-" represents an internal bond in a monomer residue.

[0227] The polymer framework may be a homopolymer of a single monomer, or a copolymer of two or more different monomers.

[0228] The polymer framework can in principle be built up from a large number of well-known monomers which can be found in any book on polymer chemistry.

[0229] Specifically, in a preferred embodiment, the nanostructure of the present application includes a polymer with a random branching and cross-linking pattern, which is in contrast to cascade polymers (such as dendritic macromolecules or dendritic alcohols) or macromolecules (such as proteins), which all have a molecularly well-defined structure in which substantially all molecular entities are the same. The advantage of this method is that it is possible to produce nanostructures with a minimum size as low as 13nm in a cost-effective, reliable and relatively simple manner. Although it is possible to reach the required minimum size for nanostructures with well-defined molecular entities, it is very expensive and cumbersome to do so. An example is the largest dendritic polymer PAMAM-G10 that seems to be commercially available, which is said to have a hydrodynamic diameter of 13.5nm, and a 100 mg research sample costs about €4000 (Sigma-Aldrich, prod no.536776), which only reaches the lower part of the expected size range of 13nm-90nm of the nanostructure according to the present application. It is estimated that the production cost of the nanostructure of the present application is less than 1% of the above price. In addition, the special advantage of the method of the present application is that chromatography purification is usually not required.

[0230] In a specific embodiment, wherein the nanostructure comprises a polymer having a random branching and crosslinking pattern, the number of bonds between monomer residues is unusually high for the polymer. In this case, the number of bonds between monomer residues is on average more than two bonds per monomer; or more than three bonds per monomer. Even numbers as high as 4 to 5 or less than but close to 6 may be considered. It will be apparent to those skilled in the art that even if monomers with crosslinking or branching potential are used as monomers for producing nanostructures according to the present application, not all potential is realized in practice, and therefore some residual groups with crosslinking or branching potential will remain in the structure of the central portion.

[0231] According to the present application, it is generally difficult to accurately determine the average number of bonds between monomer residues in nanostructures, but information from elemental composition, density measurements, NMR and AFM imposes some constraints on it, and as mentioned above, it is clear that the number of bonds between monomer residues is very high.

[0232] In one embodiment, the nanostructure comprises a homopolymer wherein there are 6 groups with bonding potential in the monomer and wherein 3 to 5 of the groups actually form bonds with other monomer residues.

[0233] In another embodiment, the average number of bonds between monomer residues is between 3 and 5.9.

[0234] Preferably, at least 90% of the monomer residues are residues according to formula (II):

[0235] {(OR 1 )(OR 2 )PO}2-(C){(CH2) n Si(OR 3 )3}{(CH2) n Si(OR 3 )3}(II)

[0236] Each R 1 and R 2 independently selected from the group consisting of a negative charge and H; each R 3 are independently selected from the group consisting of a negative charge, H, and a covalent bond to a polymer framework; wherein at least 3 R 3 is a bond to the polymer framework; and n is an integer from 1 to 5.

[0237] Preferably, at least 3 R 3 The -groups are bonds to the polymer framework.

[0238] Preferably, n=3.

[0239] Preferably, 3 R 3 The - group is a bond to the polymer framework; and n=3.

[0240] Preferably, 4 R 3 The - group is a bond to the polymer framework; and n=3.

[0241] Preferably, 5 R 3 The - group is a bond to the polymer framework; and n=3.

[0242] Preferably, all 6 R 3 - groups are all bonds to the polymer framework; and n=3.

[0243] Preferably, all R3 The - groups are independently selected from the group consisting of a negative charge, H and a bond to the polymer framework.

[0244] Preferably, all R 3 - groups are independently selected from the group consisting of negative charge, H and a bond to the polymer framework; and n=3.

[0245] Typically, at least 200 chelating groups are present in each nanostructure, arranged in a manner that allows for chelation of one or more multivalent charged cations.

[0246] The chelating groups can be randomly distributed throughout the nanostructure and, depending on chance, arranged in a way that allows chelation of multivalent charged cations (see Figure 2 ). When relying on chance, it is preferred to incorporate a large excess of chelating groups into the nanostructure so that the probability of forming clusters of chelating groups with high chelating ability is increased.

[0247] As mentioned above, the chelating groups present in the nanostructures of the present application are groups according to formula (I) as defined above. When incorporated into the polymer framework, in particular as geminal phosphonates, and allowing the binding of multivalent charged cations, these chelating groups strongly bind cations. In Example 4, it is shown how the nanostructures including geminal phosphonates compete favorably with the strong chelator EDTA.

[0248] Preferably, the phosphonate groups are substantially completely hydrolyzed to their acid form and subsequently ionized to a degree ranging from partial to complete depending on the pH of the surrounding medium.

[0249] If the phosphonate groups are partially present in their ester form, the nanostructures were found to bind metal ions less strongly.

[0250] As described herein, nanostructures comprising phosphonate groups bind the multivalent cations best at neutral or alkaline pH. This suggests that the anionic form of the hydrolyzed phosphonate plays an important role at least partially or sometimes even completely in the binding of the metal ions.

[0251] When incorporated into nanostructures, it is advantageous if the phosphonate ester is hydrolyzed predominantly or completely to the phosphonic acid. Figure 4 NMR data supporting essentially complete hydrolysis of the phosphonate are shown in .

[0252] In one embodiment, the phosphonate ester is largely hydrolyzed to phosphonic acid when present in the nanostructure, such as greater than 50%, or greater than 90%, or greater than 95%.

[0253] Not only phosphonic acid esters or acids but also phosphonic acid amides come into consideration as part of the material or as starting materials.

[0254] In another embodiment, the dried sample of the nanostructure has a g / cm 3 -1.7g / cm 3 , for example 1.4g / cm 3 -1.68g / cm 3 , for example 1.5g / cm 3 -1.67g / cm 3 , for example 1.6 g / cm 3 -1.65g / cm 3 density.

[0255] The very high density (1.469 g / cm 3 ) is consistent with the generally very high density of phosphonic acid (1.3 g / cm 3 -2.0g / cm 3 ), which is in contrast to the more normal density of phosphonates (typically about 1.1 g / cm 3 )on the contrary.

[0256] Coated spherical nanostructures

[0257] In some embodiments, the nanostructures include a coating. The coating contributes to the biocompatibility of the nanostructure. Preferably, the coating is a hydrophilic coating. Typically, the coated nanostructures as described herein have an average hydrodynamic diameter of 18nm-100nm, such as 20nm-50nm, such as 25nm-35nm.

[0258] The coating may include polyethylene glycol (PEG). Each polyethylene glycol chain may include 10 to 150 ethylene glycol residues, preferably 20 to 100, such as 30 to 50 ethylene glycol residues, such as 45 ethylene glycol residues.

[0259] Preferably, the coating comprises a coating monomer residue comprising 2 silicon atoms and 2 polyethylene glycol chains, each polyethylene glycol chain comprising 20 to 100 ethylene glycol units.

[0260] In a specific embodiment, the coating comprises a coating monomer residue comprising one or more polyethylene glycol chains and one or more silicon atoms connected by an organic linker. The organic linker can be a hydrocarbon. The organic linker can also include an ether bond. The silicon atom in the monomer can be present in a reactive siloxane group, such as -Si(OEt)3, -Si(OMe)3 or -SiCl3.

[0261] When the coating comprises a coating monomer residue, and the coating monomer residue comprises a silicon atom, the coating monomer residue is bonded to the remainder of the nanostructure via a siloxane bond.

[0262] The coating can be grafted onto the nanostructures by reaction between the nanostructures and a coating monomer comprising a reactive siloxane group (eg, -Si(OEt)3, -Si(OMe)3, or -SiCl3).

[0263] The preferred coating monomer is [(m-PEG x OCH2)2C]-CH2CH2CH2-Si(OEt)3], wherein m is an abbreviation for methyl and x is an integer between 10 and 150, such as between 20 and 100, such as between 30 and 50, for example 45 ethylene glycol residues.

[0264] Other preferred coating monomers are m-PEG x -CH2CH2CH2-Si(OEt)3, wherein m is the abbreviation for methyl and x is an integer between 10 and 150, such as between 20 and 100, such as between 30 and 50, for example 45 ethylene glycol residues.

[0265] Other preferred coating monomers are 1-(ω-methyl-(ethyleneoxy) x -methyl)-3,5-bis(3-(triethoxysilyl)propoxy)-benzene, wherein x is an integer between 10 and 150, such as between 20 and 100, such as between 30 and 50, for example 45; and 1,7-bis(triethoxysilyl)-4,4-bis(ω-methyl-(ethyleneoxy) x -methyl)-heptane, wherein x is an integer between 10 and 150, such as between 20 and 100, such as between 30 and 50, for example 45.

[0266] Pharmaceutical compositions comprising coated spherical nanostructures

[0267] According to the present application, the pharmaceutical composition comprising a plurality of spherical nanostructures (which further comprises a coating) is preferably prepared as a solution.

[0268] Typically, when used for imaging and / or cancer therapy, the spherical nanostructures further include a radioactive isotope. Depending on the application, different radioactive isotopes are used. The composition can include a nanostructure that includes a single radioactive isotope, or two or more different types of radioactive isotopes. Radioactive isotopes suitable for different applications, also called radionuclides, have been listed above.

[0269] In one embodiment, the alkoxysilanes are separated by 1 to 10 carbon atoms or 3 to 9 carbon atoms.

[0270] In another embodiment, the alkoxysilanes are separated by 7 carbon atoms.

[0271] In a preferred embodiment, the polymer framework is derived from 1,7-bis-(triethoxysilyl)-4,4-bis-(dimethylphosphonate)-heptane. The polymer framework may be formed by hydrolysis condensation polymerization.

[0272] In another preferred embodiment, the polymer framework is derived from 1,7-bis-(triethoxysilyl)-4,4-bis-(dimethylphosphonate)-heptane with a purity of 80% or more, or 85% or more, or 90% or more, or 95% or more, or 96% or more.

[0273] When a nanostructure is formed by linking a large number of monomers into a polymer network, the residues of the monomers are called monomer residues. They still retain the basic covalent bonding pattern of the original free monomers, but the formation of the linkage changes the groups directly involved in the linkage.

[0274] Process for purifying 1,7-bis(triethoxysilyl)-4,4-bis(dimethoxyphosphonate)heptane

[0275] As discussed below, the purity of the monomers affects the quality of the nanostructures produced by the method disclosed below (Example 1).

[0276] As discussed below, when nanostructures are produced by the methods disclosed below, the use of higher purity monomers can produce higher quality nanostructures.

[0277] Therefore, methods were developed for purifying 1,7-bis-(triethoxysilyl)-4,4-bis-(dimethylphosphonate)heptane to very high purities, such as greater than 80%, greater than 85%, greater than 90%, greater than 95%, or greater than 96%.

[0278] The method is suitable for large-scale production of moisture-sensitive, reactive, high-boiling, heat-sensitive oils, such as several kilograms of production under industrial conditions. It is noteworthy that all standard purification methods are not suitable for this material. Chromatography on silica gel fails due to the reactivity of triethoxysilane, and large-scale reversed-phase chromatography fails due to the need for an aqueous mobile phase. Extraction is also the case. Crystallization does not work on oils, and the material is too sensitive to heat to withstand the long-term heating conditions of vacuum distillation (as shown in Example 3).

[0279] The method for purifying 1,7-bis(triethoxysilyl)-4,4-bis(dimethoxy-phosphonate)heptane of the present application comprises the following steps:

[0280] (a) providing a solution of impure 1,7-bis(triethoxysilyl)-4,4-bis(dimethoxyphosphonate)heptane in a polar aprotic solvent;

[0281] (b) separating the solution and insoluble matter in step (a);

[0282] (c) concentrating the solution obtained in step (b) to provide a residue;

[0283] (d) dissolving the residue obtained in step (c) in a non-polar solvent;

[0284] (e) separating the solution obtained in step (d) from the insoluble matter;

[0285] (f) removing water from the solution obtained in step (e);

[0286] (g) concentrating the dried solution obtained in step (f) to obtain a second residue;

[0287] (h) subjecting the residue obtained in step (g) to a short straight-through vacuum distillation; and

[0288] (i) collecting the straight-through fraction from step (h), comprising purified 1,7-bis(triethoxysilyl)-4,4-bis(dimethoxyphosphonate)heptane.

[0289] The aprotic solvent in step (a) can be a nitrile, such as acetonitrile and propionitrile; a ketone, such as acetone and methyl ethyl ketone; an ester, such as ethyl acetate and isopropyl acetate; or a polar ether, such as THF (tetrahydrofuran) and Me-THF (methyl-tetrahydrofuran). In a preferred embodiment, the aprotic solvent in step (a) is acetonitrile.

[0290] Specifically, step (a) can be carried out by dissolving crude 1,7-bis-(triethoxysilyl)-4,4-bis-(dimethylphosphonate)-heptane in acetonitrile. Impure 1,7-bis-(triethoxysilyl)-4,4-bis-(dimethoxyphosphonate)-heptane can be dissolved in acetonitrile at a concentration of 5% (w / v) to 20% (w / v), such as 7% (w / v) to 15% (w / v), such as 10% (w / v), where (w / v) means weight / volume.

[0291] The separation step (b) can be performed, for example, by filtration, sedimentation and decantation.

[0292] Step (c) may be performed by evaporation.

[0293] The non-polar solvent in step (d) may be a cyclic or non-cyclic hydrocarbon or a hydrocarbon mixture.

[0294] In step (d), the residue obtained in step (c) may be dissolved in an alkane.

[0295] In step (d), the residue obtained in step (c) may be dissolved in a lower alkane.

[0296] Examples of suitable cyclic hydrocarbons are cyclohexane and cycloheptane.

[0297] Examples of suitable acyclic hydrocarbons are pentane, hexane and heptane. Specifically, in step (d), the residue obtained in step (c) is dissolved in heptane. The residue obtained in step (c) can be dissolved in heptane at a concentration of, for example, 5% (w / v) to 20% (w / v), for example, 7% (w / v) to 15% (w / v), for example, 10% (w / v), where (w / v) means weight / volume.

[0298] The separation step (e) can be performed by, for example, filtration, sedimentation and decantation.

[0299] In step (f), the reaction mixture may be prepared by evaporation or in, for example, The molecular sieve desiccant dries the solution obtained in step (e) to remove water. When a molecular sieve is used, step (g) may be performed by passing the first separation solution through the molecular sieve.

[0300] Step (h) of short-path vacuum distillation is preferably carried out by removing impurities by falling film vacuum in a temperature range of 150°C to 190°C, such as 160°C to 180°C, or 165°C to 175°C.

[0301] The precipitation steps (steps (a) and (d)) are useful for removing oligomeric materials that may clog the distillation apparatus. It is worth noting that normal vacuum distillation is not feasible for 1,7-bis-(triethoxysilyl)-4,4-bis-(dimethylphosphonate)-heptane, as it has been found that this compound decomposes rapidly at the temperature required for boiling even under vacuum (Example 3).

[0302] To solve this difficult purification problem, a two-stage process involving selective precipitation of impurities and subsequent falling film distillation was developed. The specific method of falling film distillation is to expose the material to high temperature for only a few seconds, which is very short for thermal degradation. Some other forms of the broader concept of "short path distillation" with short retention time at high temperature (including wiped film distillation method) are also suitable.

[0303] To remove low boiling impurities, in step (h) the mixture of intermediate purity is passed directly through a distillation apparatus to evaporate the impurities.

[0304] An advantage of falling film distillation is that it is a technique that can be used from laboratory scale to production plant scale.

[0305] Distillation can be performed in two alternative ways, including one step or two steps: in the first step, the temperature of the heating element is set to 150°C to 165°C, and the crude product is passed through the equipment. Then, low-boiling impurities lacking certain structural features (such as silane groups) can be removed and collected as distillates, and the purified product is retained. In the optional second step, the heating element is set to a higher temperature, such as 170°C to 190°C, and the product purified once is passed through the equipment again. The product is then evaporated and collected as a distillate and non-volatiles are retained. This second step is advantageous because the production of many silanes (such as 1,7-bis-(triethoxysilyl)-4,4-bis-(dimethylphosphonate)-heptane) may involve a platinum-catalyzed hydrosilylation step and may contain unacceptable amounts of platinum residues. They are non-volatile and are removed in the second step.

[0306] In a specific embodiment, 1,7-bis-(triethoxysilyl)-4,4-bis-(dimethylphosphonate)-heptane is purified by the following sequence: in step (a), the crude material is dissolved in acetonitrile and the insoluble material is separated by filtration (step (b)), followed by evaporation of the solvent (step (c)), followed by dissolving the resulting material in a lower alkane in step (d), separating the insoluble material by filtration (step (e)), followed by removal of water by molecular sieves (step (f)) and removal of the molecular sieves by filtration, followed by evaporation of the solvent (step (g)), followed by vacuum descending membrane distillation in step (h), heating the heating element to 150°C to 175°C and collecting the concentrate.

[0307] In another specific embodiment, 1,7-bis-(triethoxysilyl)-4,4-bis-(dimethylphosphonate)-heptane is purified by the following sequence: in step (a), the crude material is dissolved in acetonitrile at a concentration of 7% (w / v) to 15% (w / v) and the insoluble material is separated by sedimentation and decantation, followed by filtration (step (b)), followed by evaporation of the solvent (step (c)), and then in step (d), the resulting material is dissolved in heptane at a concentration of 7% (w / v) to 15% (w / v) and the insoluble material is separated by sedimentation and decantation (step (e)), followed by drying over activated molecular sieves, followed by removal of the molecular sieves by filtration (step (f)), followed by evaporation of the solvent (step (g)), followed by falling film distillation under vacuum in step (h), heating the heating element to 165° C. and collecting the concentrate (step (i)).

[0308] In another specific embodiment, 1,7-bis-(triethoxysilyl)-4,4-bis-(dimethylphosphonate)-heptane is purified by the following sequence: in step (a), the crude material is dissolved in acetonitrile at a concentration of 10% (w / v) and the insoluble material is separated by sedimentation and decantation, followed by filtration (step (b)), followed by evaporation of the solvent (step (c)), followed by dissolving the resulting material in heptane at a concentration of 10% (w / v) and separating the insoluble material by sedimentation and decantation in step (d), followed by filtration (step (e)), followed by drying over activated molecular sieves, followed by removal of the molecular sieves by filtration (step (f)), followed by evaporation of the solvent (step (g)), followed by falling film distillation under vacuum in step (h), heating the heating element to 165° C. and collecting the concentrate (step (i)).

[0309] Alternatively, 1,7-bis-(triethoxysilyl)-4,4-bis-(dimethylphosphonate)-heptane can be purified by the following sequence: (i) dissolving the crude material at a 10% (w / v) concentration in heptane as in step (d) above, and (ii) separating the insoluble material by settling and decantation, followed by filtration (as in step (e) above) followed by (iii) evaporation of the solvent (as in step (g) above), and then (iv) treating the resulting material at a 10% (w / v) concentration as in step (a) above. The method comprises the steps of: (i) dissolving the precipitate in acetonitrile to a certain degree, and (v) separating the insoluble material by settling and precipitation, followed by filtration (as in step (b) above), and (vi) drying with activated molecular sieves, followed by removal of the molecular sieves by filtration (as in step (f) above), and (vii) evaporating the solvent (as in step (c) above), and (viii) performing falling film distillation under vacuum in this step (as in step (h) above), wherein the heating element is heated to 165° C., and (ix) collecting the concentrate (as in step (i) above).

[0310] It is contemplated that only the short straight-through vacuum distillation used in step (h) would be used to purify the impure 1,7-bis(triethoxysilyl)-4,4-bis(dimethoxyphosphonate)heptane, especially if the impure 1,7-bis(triethoxysilyl)-4,4-bis(dimethoxyphosphonate)heptane comprises only a small amount of macromolecular impurities. However, it has been found that when 1,7-bis(triethoxysilyl)-4,4-bis(dimethoxyphosphonate)heptane is synthesized using known methods, oligomeric impurities are always present in the impure 1,7-bis(triethoxysilyl)-4,4-bis(dimethoxyphosphonate)heptane.

[0311] As described above, step (h) may include the further step of purifying the 1,7-bis(triethoxysilyl)-4,4-bis(dimethoxyphosphonate)heptane by falling film distillation under vacuum, wherein the heating element is heated to above 185° C. and the distillate is collected. In this case, the purified material 1,7-bis-(triethoxysilyl)-4,4-bis-(dimethoxyphosphonate)heptane obtained has a lower concentration of inorganic impurities.

[0312] An impurity present in the impure 1,7-bis-(triethoxysilyl)-4,4-bis(dimethoxyphosphonate)heptane is a byproduct formed during the production of the monomer. HPLC analysis of a crude preparation of 1,7-bis-(triethoxysilyl)-4,4-bis(dimethoxyphosphonate)heptane showed 54% purity and Figure 5 The HPLC trace of this sample is shown in A. Figure 5 A sample of material purified to 97% according to the method described above (see Example 2 for details) is shown in B. It is clear that the purity has been improved. This is an important advantage when 1,7-bis(triethoxysilyl)-4,4-bis(dimethoxyphosphonate)heptane is subsequently used to produce nanostructures according to the present application.

[0313] 1,7-bis(triethoxysilyl)-4,4-bis(dimethoxyphosphonate)heptane purified as described herein can be used to produce a plurality of spherical nanostructures according to the present application.

[0314] Method for producing a plurality of spherical nanostructures

[0315] The method for producing a plurality of spherical nanostructures according to the present application is outlined in Figure 8 It has been found that, even when carried out on a large scale, the method can produce nanostructures of a specific size and dispersion that are of a quality suitable for use in imaging and radiotherapy.

[0316] Briefly, the method for producing a plurality of spherical nanostructures according to the present application involves dissolving the monomer in a water (step 001) / solvent mixture (002), and heating the solution (003) for a long time ( Figure 8 ).

[0317] In detail, the method comprises the following steps:

[0318] (a) providing a solution comprising a monomer in a mixture of water and a lower alcohol, wherein the monomer is a monomer according to formula (II)

[0319] {(OR 1 )(OR 2 )PO}2-(C){(CH2) n Si(OR3 )3}{(CH2) n Si(OR 3 )3}(II)

[0320] in

[0321] Each R 1 and R 2 are independently selected from the group consisting of lower alkyl and aryl; and

[0322] Each R 3 are independently selected from the group consisting of lower alkyl and aryl; and

[0323] n is an integer between 1 and 5; and

[0324] (b) subjecting the solution of step (a) to a temperature of 110° C. to 160° C. for a period of time such that the growth rate of the nanostructures is significantly lower than the initial growth rate.

[0325] Step (a) corresponds to Figure 8 Steps 001 and 002 in , and step (b) corresponds to Figure 8 Step 003 in .

[0326] Preferably, R 1 and R 2 -CH3, R 3 The -group is -CH2-CH3, and n=3.

[0327] In step (b) the temperature may be between 115°C and 145°C, for example between 125°C and 140°C.

[0328] In step (b), the time period may be between 30 hours and 300 hours, for example between 40 hours and 250 hours, for example between 45 hours and 225 hours, for example between 48 hours and 200 hours. In some cases, this time period may be even shorter, 25 hours, 20 hours, 15 hours, 10 hours or 5 hours.

[0329] In a preferred embodiment, in step (b), the time period is between 45 hours and 50 hours.

[0330] Preferably, in step (b), the solution of step (a) is subjected to a temperature of 125°C for a period of 200 hours, or to a temperature of 140°C for a period of 48 hours.

[0331] Preferably, in step (b), the temperature is 140° C. and the heating time is 45 to 50 hours.

[0332] Optionally, the method further comprises: step (c), cooling the solution of step (b) to ambient temperature.

[0333] When a nanostructure is formed by linking a large number of monomers into a polymer network, the residues of the monomers are called monomer residues. They still retain the basic covalent bonding pattern of the original free monomers, but the formation of the linkage changes the groups directly involved in the linkage.

[0334] In the resulting nanostructure, the monomer residues are incorporated into the polymer framework via Si-O-Si bonds, wherein the silicon atom is a silicon atom in a structure according to formula (II).

[0335] Chelating groups include geminal bisphosphonate groups, ie, two phosphonate groups attached to the same carbon atom.

[0336] It is contemplated that two, three or several different polymer frameworks produced according to the present method can be mixed in any chemically compatible monomer combination by mixing the monomers prior to polymerization or by grafting one polymer onto another.

[0337] The degree of polymerization (average number of monomer residues) or molecular weight of the nanostructure produced by the method disclosed herein can be precisely controlled by manipulating process parameters to produce products of desired size. Examples of these parameters are described in Example 1. It is less useful to describe the size by degree of polymerization by describing the molecular weight rather than the hydrodynamic diameter, but this is another way to conceptualize the structure. The degree of polymerization included is not intended to be a limitation but rather a reference. For example, for a nanostructure with a diameter of 17.5 nm obtained by hydrolysis and polycondensation of 1,7-bis-(triethoxysilyl)-4,4-bis-(dimethylphosphonate)-heptane according to the method described herein, the density is 1.469 g / cm 3 , the estimated degree of polymerization is about 6400 monomers and the molecular weight is about 2.5 MDa. The degree of polymerization can be measured by mass spectrometry, gel filtration or dynamic light scattering.

[0338] For impure starting materials (ie, monomers with less than 80% purity), the size of the resulting nanostructures continued to grow indefinitely, as evidenced by the formation of a precipitate, resulting in a broader size distribution (Example 10).

[0339] Alternatively, monomers of a certain purity, for example, monomers of a purity exceeding 80%, preferably exceeding 85%, more preferably exceeding 90%, even more preferably exceeding 95%, and especially exceeding 96%, may be used as the starting material.

[0340] Optionally, the solution of nanostructures produced from these monomers can be subjected to a series of size selection steps to remove unwanted large or small entities to reduce the dispersion. The size selection steps are described in more detail below.

[0341] When the monomeric silane has a sufficient purity, for example, having a purity of more than 80%, preferably more than 85%, more preferably more than 90%, even more preferably more than 95%, and especially more than 96%, the size of the resulting nanostructures tends to stabilize at a given size, which depends on the reaction conditions. When this plateau is reached, the degree of crosslinking essentially reaches the highest level it can reach, and the phosphonate is essentially completely hydrolyzed or hydrolyzed to a large extent. This is important for applying the nanostructures to radioisotope therapy and imaging products based on nanomaterials, because the fully hydrolyzed product bisphosphonic acid is the most chelated form of the phosphonate (see Example 5).

[0342] Preferably, the purity of the silane monomer is 80% or higher, such as 85% or higher, more preferably, the purity of the silane monomer is 90% or higher, even more preferably, the purity of the silane monomer is 95%, especially more than 96% or higher. Such high purity can be achieved by the purification method described herein.

[0343] It has been found that bis-(trialkoxy-)silanes carrying phosphonate groups (i.e., wherein R 3 Silanes whose groups are lower alkyl groups) are particularly useful for forming nanostructures according to the present application.

[0344] Preferably, R 1 and R 2 is independently selected from the group consisting of lower alkyl groups (i.e., alkyl groups having 1 to 8 carbon atoms), more preferably selected from the group consisting of methyl, ethyl and propyl groups, more preferably, R 1 and R 2 It is methyl.

[0345] Preferably, R 3 - groups are independently selected from the group consisting of lower alkyl groups (i.e., alkyl groups having 1 to 8 carbon atoms), more preferably selected from the group comprising methyl, ethyl and propyl, and even more preferably, R 3 The -group is an ethyl group.

[0346] Preferably, n=3.

[0347] Preferably, R 1 and R 2 is methyl and R 3 The -group is an ethyl group.

[0348] Preferably, R 1 and R 2 is methyl, R 3-The group is ethyl, and n=3.

[0349] It has been found that 1,7-bis-(triethoxysilyl)-4,4-bis-(dimethylphosphonate)-heptane is a suitable monomer, particularly when its purity is greater than 80%, or greater than 85%, or greater than 90%, or greater than 95%, or greater than 96% as measured by HPLC-ELSD. High purity promotes predictability of the polymerization process. This high purity can be achieved by the purification methods disclosed herein.

[0350] Preferably, at least 50%, such as at least 90%, of the monomer residues are 1,7-bis-(triethoxysilyl)-4,4-bis-(dimethylphosphonate)-heptane.

[0351] The mixture of water and lower alcohol can be a mixture of 5% to 50% (vol / vol), preferably 5% to 25% (vol / vol), for example 5% to 22% (vol / vol), for example 6% to 20% (vol / vol), for example 7% to 18% (vol / vol), for example 8% to 15% (vol / vol), for example 9% to 12% (vol / vol), for example 10% to 11% (vol / vol) of water in lower alcohol, the lower alcohol having 1-8 carbon atoms.

[0352] Preferably, the lower alcohol is selected from the group consisting of ethanol, 1-propanol, 2-propanol or 1,2-propylene glycol, 1,3-propylene glycol, ethylene glycol or a mixture thereof.

[0353] In one embodiment, the mixture of water and lower alcohol is a mixture of 5% to 25% (vol / vol), such as 5% to 22% (vol / vol), such as 6% to 20% (vol / vol), such as 7% to 18% (vol / vol), such as 8% to 15% (vol / vol), such as 9% to 12% (vol / vol), such as 10% to 11% (vol / vol) water in ethanol.

[0354] In another embodiment, the mixture of water and a lower alcohol is a mixture of 5% to 25% (vol / vol), such as 5% to 22% (vol / vol), such as 6% to 20% (vol / vol), such as 7% to 18% (vol / vol), such as 8% to 15% (vol / vol), such as 9% to 12% (vol / vol), such as 10% to 11% (vol / vol) of water in 1-propanol.

[0355] In another embodiment, the mixture of water and a lower alcohol is a mixture of 5% to 25% (vol / vol), such as 5% to 22% (vol / vol), such as 6% to 20% (vol / vol), such as 7% to 18% (vol / vol), such as 8% to 15% (vol / vol), such as 9% to 12% (vol / vol), such as 10% to 11% (vol / vol) of water in 2-propanol.

[0356] In another embodiment, the mixture of water and a lower alcohol is a mixture of 5% to 25% (vol / vol), such as 5% to 22% (vol / vol), such as 6% to 20% (vol / vol), such as 7% to 18% (vol / vol), such as 8% to 15% (vol / vol), such as 9% to 12% (vol / vol), such as 10% to 11% (vol / vol) of water in 1,2-propylene glycol.

[0357] In a further embodiment, the mixture of water and a lower alcohol is a mixture of 5% to 25% (vol / vol), such as 5% to 22% (vol / vol), such as 6% to 20% (vol / vol), such as 7% to 18% (vol / vol), such as 8% to 15% (vol / vol), such as 9% to 12% (vol / vol), such as 10% to 11% (vol / vol) of water in 1,3-propylene glycol.

[0358] In another embodiment, the mixture of water and lower alcohol is a mixture of 5% to 25% (vol / vol), such as 5% to 22% (vol / vol), such as 6% to 20% (vol / vol), such as 7% to 18% (vol / vol), such as 8% to 15% (vol / vol), such as 9% to 12% (vol / vol), such as 10% to 11% (vol / vol) of water in ethylene glycol.

[0359] Herein, 90.0% (vol / vol) ethylene glycol aqueous solution refers to a mixture of 90.0% (vol / vol) ethylene glycol and 10.0% (vol / vol) water.

[0360] In one embodiment, the mixture of water and lower alcohol is a mixture of 5% to 25% water in ethylene glycol.

[0361] In yet another embodiment, the mixture of water and lower alcohol is a mixture of 18% to 22% water in ethylene glycol.

[0362] In another embodiment, the mixture of water and lower alcohol is a mixture of 9% to 11% water in ethylene glycol.

[0363] A suitable solvent mixture is water / ethylene glycol in a suitable ratio, for example 50% to 95% ethylene glycol or 80% to 95% ethylene glycol or 88% to 92% ethylene glycol, i.e. 5% to 50% (vol / vol), for example 5% to 20% (vol / vol), for example 8% to 12% (vol / vol) water in ethylene glycol.

[0364] Heating may occur in a sealed pressure-resistant vessel or by reflux at atmospheric pressure.

[0365] When using low boiling point alcohols, it is necessary to work with sealed pressure vessels to achieve the required reaction temperature.

[0366] In step (b), the temperature may be maintained at 110°C to 160°C for up to 10 days.

[0367] The temperature in step (b) may be from 120°C to 145°C, for example from 120°C to 140°C.

[0368] The minimum time period in step (b) depends on the temperature, for example a temperature of 125° C. requires a heating period of 195 hours or more, while a temperature of 140° C. requires a heating period of 48 hours or more. Preferably, a longer time period than the minimum time period is used.

[0369] The minimum time period in step (b) is characterized in that after the minimum time period the growth rate of the nanostructures is significantly lower than the growth rate at the beginning of the reaction.

[0370] It will be apparent to one skilled in the art that one can determine from the growth rate at the end of step (b) and the size of the nanostructures at the end of step (b) whether the growth rate is significantly lower than the initial growth rate without first measuring the initial growth rate.

[0371] In one embodiment, the growth rate of the nanostructures at the end of step (b) is much lower than the growth rate at the beginning of step (b), for example more than 10 times lower, or more than 20 times lower, or even more than 30 times lower.

[0372] In another embodiment, the growth rate of the nanostructures at the end of step (b) is substantially zero.

[0373] In yet another embodiment, the conditions of step (b) are a temperature of 125° C. and a duration of 200 to 500 hours.

[0374] In yet another embodiment, the conditions of step (b) are a temperature of 140° C. and a duration of 40 hours to 200 hours.

[0375] It is worth noting that the silane starting material is sensitive to moisture and will gradually form oligomers if exposed to moisture (e.g., by exposure to the atmosphere or glassware). The presence of such oligomers leads to variability in the reaction rate and the final size and size distribution of the resulting nanostructures (Example 9). Therefore, measures should be taken to avoid exposing the monomers to moisture. Such measures are well known to those skilled in the art.

[0376] High quality nanostructures of given sizes between 13 nm and 90 nm, for example between 13 nm and 50 nm, or between 14 nm and 25 nm, or between 15 nm and 22 nm, or between 16 nm and 20 nm can be produced by the above disclosed methods. It is contemplated that the above disclosed methods can be used to produce nanostructures of smaller or larger sizes.

[0377] Examples of conditions are described in Example 1. An industrial and economic advantage of the process described here is that only environmentally friendly and relatively non-toxic solvents are used.

[0378] In one embodiment, the monomer concentration is 20mM-85mM, such as 30mM-80mM, such as 35mM-75mM, such as 40mM-70mM, such as 45mM-65mM.

[0379] In another embodiment, the monomer concentration is 30 mM-85 mM, such as 35 mM-80 mM, such as 40 mM-75 mM, such as 45 mM-70 mM, such as 50 mM-65 mM.

[0380] In another embodiment, the monomer concentration is 35 mM-85 mM.

[0381] In one embodiment, the monomer concentration is 20mM-85mM, such as 30mM-80mM, such as 35mM-75mM, such as 40mM-70mM, and the reflux temperature is 140° C. or higher. Preferably, in this embodiment, the reaction time is 40 hours to 140 hours, such as 40 hours to 120 hours, such as 40 hours to 100 hours, such as 40 hours to 80 hours, such as 40 hours to 60 hours, such as 40 hours to 55 hours, preferably 45 hours to 50 hours.

[0382] In another embodiment, the monomer concentration is 30mM-85mM, such as 35mM-80mM, such as 40mM-75mM, such as 45mM-70mM, and the reflux temperature is 125°C or higher. Preferably, in this embodiment, the reaction time exceeds 250 hours, such as exceeds 300 hours, such as exceeds 400 hours.

[0383] In a specific embodiment, the monomer concentration is 25 mM-85 mM, the solvent mixture is 20% (vol / vol) water in ethylene glycol, the reflux temperature is 125° C., and the reaction time is more than 250 hours.

[0384] In another specific embodiment, the monomer is 1,7-bis-(triethoxysilyl)-4,4-bis-(dimethylphosphonate)-heptane, the monomer concentration is 25mM-85mM, the solvent mixture is 80% (vol / vol) ethylene glycol in water (i.e., the ratio of water in ethylene glycol is 20% (vol / vol)), the reflux temperature is 125°C and the reaction time is more than 250 hours.

[0385] In another specific embodiment, the monomer is 1,7-bis-(triethoxysilyl)-4,4-bis-(dimethylphosphonate)-heptane, the monomer concentration is 30 mM-40 mM, the solvent mixture is 10% (vol / vol) water in ethylene glycol, the reflux temperature is 140° C. and the reaction time is about 48 hours.

[0386] In another specific embodiment, the monomer is 1,7-bis-(triethoxysilyl)-4,4-bis-(dimethylphosphonate)-heptane, the monomer concentration is 34 mM-36 mM, the solvent mixture is 10% (vol / vol) water in ethylene glycol, the reflux temperature is 140° C. and the reaction time is about 48 hours.

[0387] In another specific embodiment, the monomer is 1,7-bis-(triethoxysilyl)-4,4-bis-(dimethylphosphonate)-heptane, the monomer concentration is 34mM-36mM, the solvent mixture is 10% (vol / vol) water in ethylene glycol, the reflux temperature is 140°C and the reaction time is greater than 48 hours.

[0388] Optionally, the solution of nanostructures may be subjected to a series of size selection steps to remove undesirable large (004) or small (005) entities to reduce the dispersion. Figure 8 Steps 004 and 005 can be performed in any order and repeated any number of times in any order. The starting materials and solvent residues from the reaction mixture can also be removed at this stage.

[0389] Importantly, if the starting material (ie, monomer) has a purity greater than 80%, then a size selection step may not be required.

[0390] Ultrafiltration is a preferred size selection method, especially when used in a format commonly known as tangential flow filtration. Other ultrafiltration methods such as spin filters or dialysis can also be used, although they are less scalable.

[0391] Preferably, undesirable large nanostructures and / or aggregates (004) are removed by passing the solution through a filter with relatively large pores. The preferred nominal cut-off value of such a filter is 0.2 μm. Alternatively, the nominal cut-off value of such a filter is 1000 kDa, 500 kDa or 300 kDa.

[0392] In step (005), the desired material can be collected on a filter with a smaller pore size. The preferred pore size of step 005 is given as a nominal cutoff value, which is 300kDa, 100kDa, 50kDa, 30kDa or 10kDa, provided that when a 300kDa filter is used in step 005, the filter used in step 004 must have a larger hole. It should be noted that the nanostructure in this state has a reactive surface, and in any size selection step, excessive upward concentration should be avoided or the nanostructure may be irreversibly aggregated. This upward concentration can be avoided by ensuring that the volume is kept substantially constant during the filtration process.

[0393] In step 005, the material may be washed with several portions of a solvent (eg, water) to further remove unreacted monomers or unwanted solvent residues from steps 001, 002, or 003.

[0394] Nanostructures of a desired size range can also be selected by size exclusion chromatography (also known as gel filtration).

[0395] Use of spherical nanostructures according to the present application

[0396] The nanostructures according to the present application may be used as precursors to other materials or as intermediates in the production of other materials.

[0397] Used as an intermediate in the production of coated nanostructures

[0398] One application is as an intermediate in the production of coated nanostructures. The coating may be a coating of polyethylene glycol (PEG). Typically, the average hydrodynamic diameter of the final coated nanostructure may be between 18 nm and 100 nm, or between 20 nm and 50 nm, or between 25 nm and 35 nm.

[0399] The coated nanostructures can be used for imaging or radiation therapy.

[0400] In particular, the coated nanostructures may be used as intravenous imaging agents and / or radiotherapeutic agents.Preferably, the coated nanostructures are included in a composition suitable for such application, such as a liquid composition.

[0401] In one embodiment, the nanostructures according to the present application are used as intermediates to produce a drug comprising PEG (polyethylene glycol) coated nanostructures suitable for carrying radioisotopes for imaging and / or radiotherapy.

[0402] Example 6 describes how to prepare a coated nanostructure according to the present application that is compatible with the properties of a pharmacological product. The nanostructure can be used for tumor imaging and therapy. When used, a radioisotope is incorporated into the nanostructure. The radioisotope can be incorporated into the nanostructure before being sent to the clinic or just before being injected into the patient.

[0403] Used as intermediates in the production of pharmaceutical products

[0404] Another application is the use of the nanostructures according to the present application as intermediates in the production of pharmaceutical products. The pharmaceutical products can be used for imaging and / or radiotherapy.

[0405] Preferably, the nanostructure is a coated nanostructure as described above.

[0406] When used, the radioisotope is incorporated into the nanostructure. The radioisotope can be incorporated into the nanostructure before delivery to the clinic or just before injection into the patient.

[0407] Used as a carrier of radioisotopes

[0408] Therefore, the nanostructure according to the present application can be used as a carrier of radioisotopes.

[0409] Example

[0410] Examples of different implementations of the present application are described below.

[0411] General experimental conditions

[0412] Unless otherwise noted, materials, reagents, and solvents were obtained from commercial sources and used without further purification. Solvents were of reagent or comparable grade unless otherwise noted.

[0413] 1,7-Bis-(triethoxysilyl)-4,4-bis-(dimethylphosphonate)-heptane was prepared according to a published method (WO2013041623A1, Example 3).

[0414] HPLC (High Pressure Liquid Chromatography) of 1,7-bis-(triethoxysilyl)-4,4-bis-(dimethylphosphonate)-heptane was performed under the following conditions: Hewlett Packard series 1100 equipped with an Agilent Poroshell 120EC-C18 3.0×50 mm column, elution at 0.7 ml / min, oven temperature of 40° C., DAD detector recording at 220 nm and ELSD detector (ELSD settings: 36° C., 1.4 l N2 / min, gain=8, impactor on).

[0415] HPLC (High Pressure Liquid Chromatography) of all other compounds was performed under the following conditions: on a Hewlett Packard series 1100 equipped with an Agilent Poroshell 120EC-C18 4.6×50 mm column, DAD detector recording at 220 nm and ELSD detector (ELSD settings: 40° C., 1.4 1 N2 / min, gain=4, impactor on), using a non-linear gradient starting with 43% acetonitrile in water, 1 ml / min, oven temperature 40° C.

[0416] Equipped with Agilent Bio SEC-5 SEC was performed on a Younglin Instrument YL9100 column, eluting at 1.2 ml / min at ambient temperature, DAD detector recording at 220 nm, 280 nm and 560 nm, and ELSD detector (ELSD settings: 60° C., 1.2 1 N 2 / min, gain = 4).

[0417] DLS was measured using a Malvern Instruments Zetasizer Nano ZEN3600 and processed using the general procedure settings in the Zetasizer software.

[0418] The term "PES" is an abbreviation for polyethersulfone.

[0419] The term "GF / A filter" is an abbreviation for glass microfiber filter, grade GF / A.

[0420] The term "RPM" is an abbreviation for revolutions per minute.

[0421] The term "PTFE" as used herein is an abbreviation for polytetrafluoroethylene.

[0422] Example 1 - Synthesis of Nanostructures

[0423] Three different variants of the method for producing the spherical nanostructures of the present application are disclosed below ("Method 1", "Method 2" and "Method 3"). The process parameters, such as monomer concentration and purity, solvent properties and reaction time, vary between these different variants.

[0424] Method 1 describes a method performed at atmospheric pressure, suitable for large-scale synthesis of nanostructures. Method 2 describes a method in a closed container at pressures above 1 atmosphere, suitable for small-scale synthesis of nanostructures. Method 3 is a reference method outside the scope of this application, in which the nanostructures are collected before they have reached a stable size and before the phosphonate and alkoxysilane are fully hydrolyzed.

[0425] Example 1A, Representative Example of "Method 1" (After Long Boil)

[0426] The 1-liter jacketed reactor was equipped with a mechanical stirrer, a temperature probe, and a reflux condenser, with a vacuum nitrogen manifold connected to the top. 16.3 g of 97% pure 1,7-bis-(triethoxysilyl)-4,4-bis(dimethylphosphonate) heptane and 748.3 g of 90.0% (vol / vol) ethylene glycol aqueous solution were charged into the reactor. The solution was degassed. Under stirring, the jacket temperature was raised to 146°C within 25 min, during which the solution became clear. After maintaining the set jacket temperature for 25 minutes, a gentle reflux was obtained. The reaction mixture was maintained at reflux for 47.5 hours and then cooled to 20°C. DLS sampling was performed after 45 hours and 47 hours of reflux, and the average diameters obtained were 18.1 nm and 18.2 nm, respectively. Average diameter 18.2 nm.

[0427] [P](ICP-OES)=69mM, [Si](ICP-OES)=74mM.

[0428] Example 1B, Representative Example of "Method 2" (After Long Boil)

[0429] 7.91 g of 96% pure 1,7-bis(triethoxysilyl)-4,4-bis(dimethylphosphonate)heptane and 182.5 ml of 80% (vol / vol) ethylene glycol aqueous solution were placed in a 250 ml bomb vial. The solution was degassed and placed under a nitrogen atmosphere. The bomb vial was sealed and heated to 125°C in an oil bath for 264 hours. The solution was filtered through a glass fiber filter. The average diameter was 17.5 nm. [P](ICP-OES)=136mM, [Si](ICP-OES)=154mM.

[0430] Example 1C, representative example of "Method 3" (with short boiling) - reference method not within the scope of this application

[0431] In a round bottom flask, 4.53 g of 1,7-bis(triethoxysilyl)-4,4-bis(dimethylphosphonate)heptane with an estimated purity of 90% was mixed with 667 μl of a 23 mg / ml solution of rhodamine isothiocyanate in ethylene glycol, 71 ml of ethylene glycol and 17.9 ml of water. The solution was degassed and divided into 12 ml portions in sealed reaction bottles. The reaction bottles were heated in a preheated (125°C) oil bath for 43 hours. Average diameter 15.5 nm. [P](ICP-OES)=164mM, [Si](ICP-OES)=165mM.

[0432] Examples 1D to 1Z

[0433] Further experiments were performed in which the method parameters of the three above-mentioned variations were varied.

[0434] The results of embodiments 1A-1Z are shown in Table 1.

[0435] Table 1. Results of using different reaction conditions in the method for producing nanostructures according to the present application

[0436] The "monomer" is 1,7-bis(triethoxysilyl)-4,4-bis(dimethylphosphonate)heptane

[0437] The examples marked with * provide nanostructures outside the scope of this application and are provided as reference examples.

[0438]

[0439]

[0440] As can be seen from Table 1, the hydrodynamic diameter of the nanostructure can be controlled by controlling the concentration of the monomer at the beginning of the synthesis, as in Method 1 (1A, 1Q-1W) or Method 2 (1B, 1D-P). In addition, the hydrodynamic diameter of the nanostructure can be controlled by controlling the concentration of water in the reaction medium (1X-1Z).

[0441] Example 2 - Purification of 1,7-bis(triethoxysilyl)-4,4-bis(dimethylphosphonate)heptane

[0442] 107 g of 1,7-bis(triethoxysilyl)-4,4-bis(dimethylphosphonate)heptane with an estimated purity of 54% was charged into a dry three-necked 2-liter round-bottom flask. Anhydrous acetonitrile (1070 ml) was added under vigorous stirring. After 30 minutes of vigorous stirring, the stirring speed was reduced to about 40 RPM and allowed to stand overnight. The solution was cannulated filtered through a 0.2 μm PTFE filter and the solvent was removed in vacuo to give 98.9 g of a light yellow oil.

[0443] The oily matter obtained is mixed with heptane (1000ml) so as to form a viscous precipitation immediately. The supernatant is poured into a new flask, precipitated with heptane washing, and washings are added to the supernatant. The solution is stirred overnight gently, and then the clear supernatant is decanted. Shaking table is used to stir gently, the solution is dried 8 days with fresh activated molecular sieve, then first filtered by glass fiber filter, finally filtered by sleeve tube by 0.2 μm PTFE filter. Vacuum removes solvent to produce 74g transparent oily matter.

[0444] 61.5 g of the resulting oil was subjected to falling film distillation at a pressure of 1.3 mbar, heated to 160° C. with a heating element, at a feed rate of about 10 ml / h, using a homemade distillation apparatus similar to the distillation apparatus sold by Sigma Aldrich (e.g., Sigma Aldrich catalog number Z156604 provided by Merck KGaA, Darmstadt, Germany), to obtain 44 g of a concentrate. The concentrate was 97% pure 1,7-bis(triethoxysilyl)-4,4-bis(dimethylphosphonate)heptane as determined by HPLC-ELSD.

[0445] Example 3 - Failed attempt to vacuum distill 1,7-bis-(triethoxysilyl)-4,4-bis-(dimethylphosphonate)-heptane - Reference method not within the scope of this application

[0446] In a 50 ml two-necked round-bottom flask equipped with a distillation head, a Liebig condenser and a receiving flask, 4.6 g of crude 1,7-bis-(triethoxysilyl)-4,4-bis-(dimethylphosphonate)-heptane were added. An oil pump vacuum (0.1 mbar) was applied and the distillation flask was gradually heated from 40° C. to a temperature of 210° C. in an oil bath. The maximum internal temperature reached 142° C. No product was collected in the receiving flask, and the residue in the distillation flask was very dark brown and was not suitable for use as a starting material for nanostructures.

[0447] Thus, it was demonstrated that crude 1,7-bis-(triethoxysilyl)-4,4-bis-(dimethylphosphonate)-heptane could not be purified using conventional vacuum distillation.

[0448] Example 4 - Determination of the Chelation Strength of Coated Nanostructures of Various Sizes by EDTA Competitive Chelation Test

[0449] By synthesizing nanostructures according to the method of the present application ("by long boiling" as detailed in Example 1), nanostructures of 7.1 nm, 12.5 nm, 17.5 nm and 23 nm were obtained, corresponding to test items 4A, 4B, 4C and 4D, respectively.

[0450] The test items were coated and loaded with metal ions (M) by a process similar to that used in Example 6 below. 3+ ), such as yttrium (Y) or lutetium (Lu). The metal ion-loaded nanostructures are then diluted with 50 mM Tris buffer (pH 7.4) to a yttrium or lutetium concentration of 0.2 mM. A 2 mM ethylenediaminetetraacetic acid (EDTA) solution, pH 7.5, in 50 mM Tris buffer is prepared for testing metal ions bound to the nanostructures using 10 molar equivalents of excess EDTA, or a 1 mM EDTA solution is used for testing metal ions bound to the nanostructures using 5 molar equivalents of excess EDTA. 280 μL of the diluted metal ion-loaded nanostructures are mixed with 280 μL of the prepared EDTA solution and allowed to stand for 1 hour at room temperature (1 hRT) or for 24 hours at 37°C (24h37C). After incubation, 50 μl of the mixture is removed and labeled XXX-pre (XXX = selected number, pre = before filtration). The remaining mixture solution is placed in a 0.5 ml Amicon 3kDa spin filter and centrifuged at 12000×g for 15 min. The permeate is labeled as XXX-post (post=after filtration). The metal ion concentration in the samples xxx-pre and xxx-post is determined by ICP-OES. The percentage of metal ions remaining bound to the nanostructure is calculated using the following formula, which is called metal ion stability%. The value obtained is called the chelation strength of the nanostructure, and the greater the value, the stronger the chelation strength of the nanostructure.

[0451]

[0452] Table 2. Chelation strength of coated nanostructures. "Core" refers to the uncoated nanostructures before coating; 1hRT refers to incubation at room temperature for 1 hour; 24h37C refers to incubation at 37°C for 24 hours

[0453]

[0454] As can be seen from Table 2, compared with the coated nanostructure with a chelating core larger than 13 nm, the coated nanostructure with a chelating core smaller than 13 nm synthesized by the method according to the present application has a significantly weaker chelating strength.

[0455] Example 5 - Comparison of Chelating Strength of Nanostructures After Short and Long Boiling

[0456] Nanostructures were synthesized by a process similar to that of Examples 1B and 1C to obtain nanostructures of 12.4, 12.5, 17.8, and 17.5 nm, corresponding to Test Items 5A, 5B, 5C, and 5D, respectively. Test Items 5B and 5D were synthesized by a process similar to that of Example 1B, and Test Items 5A and 5C were synthesized by a process similar to that of Example 1C.

[0457] The test items were coated and loaded with metal ions (M) by a procedure similar to that used in Example 6 below. 3+ ), such as yttrium (Y) or lutetium (Lu). The metal ion-loaded nanostructures are then diluted with 50 mM Tris buffer (pH 7.4) to a yttrium or lutetium concentration of 0.2 mM. A 2 mM ethylenediaminetetraacetic acid (EDTA) solution, pH 7.5, in 50 mM Tris buffer is prepared for testing metal ions bound to the nanostructures using an excess of 10 molar equivalents of EDTA, or a 1 mM EDTA solution is used for testing metal ions bound to the nanostructures using an excess of 5 molar equivalents of EDTA. The greater the excess of EDTA, the more stringent the test. 280 μL of the diluted metal ion-loaded nanostructures are mixed with 280 μL of the prepared EDTA solution and allowed to stand for 1 hour at room temperature (1 hRT) or for 24 hours at 37°C (24h37C). After incubation, 50 μl of the mixture is removed and labeled XXX-pre (XXX = selected number, pre = before filtration). The remaining mixture solution was placed in a 0.5 ml Amicon 3kDa optional filter and centrifuged at 13.4kRPM (=12000×g) for 15 min. The permeate was labeled XXX-post (post=after filtration). The metal ion concentrations in samples xxx-pre and xxx-post were determined by ICP-OES. The percentage of metal ions remaining bound to the nanostructure was calculated using the following formula, which is called metal ion stability%. The value obtained is a measure of the chelation strength of the nanostructure. The larger the value, the stronger the chelation strength of the nanostructure.

[0458]

[0459] Table 3. Chelation strength of coated nanostructures. "Core" refers to uncoated nanostructures. Test items 5A, 5B, and 5C marked with * are reference items and are not within the scope of this application.

[0460]

[0461] Table 3 shows that the long-boiled nanostructures loaded with metal ions synthesized according to the method of the present application (described in detail in Example 1A or 1B) have better metal ion stability than the nanostructures of the same size prepared by the short-boiled method 1C. This confirms the better chelating strength of the nanostructures of the present application.

[0462] Example 6 - Biodistribution study of coated nanostructures in a tumor-bearing mouse model

[0463] Representative preparation of test items: Test item C

[0464] The nanostructures were synthesized by a process similar to that of Example 1B: using 95 mM 1,7-bis(triethoxysilyl)-4,4-bis(dimethylphosphonate)-heptane solution, nanostructures with a diameter of 23.0 nm were obtained. To prepare the coated nanostructures, a sample of 10 ml of the resulting nanostructure solution (i.e., 0.95 mmol, 1,7-bis(triethoxysilyl)-4,4-bis(dimethylphosphonate)-heptane) was placed in a bottle and heated to 100° C. in an oil bath. After 20 minutes, 809 mg of bis(triethoxysilyl)methane (2.38 mmol, 2.5 equivalents of 1,7-bis(triethoxysilyl)-4,4-bis(dimethylphosphonate)heptane) was added with vigorous stirring. Heating was maintained for 4 hours with relatively gentle stirring. Average diameter 25.7 nm.

[0465] A sample of 1.025 ml of the resulting nanostructure solution (i.e., 0.097 mmol 1,7-bis(triethoxysilyl)-4,4-bis(dimethylphosphonate)heptane) was diluted to 7.5 ml with 80% (vol / vol) aqueous ethylene glycol in a 2-necked round bottom flask with a vertical neck equipped with a reflux condenser connected to a vacuum nitrogen manifold on top and a side neck stopper with a septum. The solution was heated in a preheated 110° C. oil bath for 10 minutes, and then 200 μl of 50% (w / w) 1,7-bis-(triethoxysilyl)-4,4-bis(ω-methyl-(ethyleneoxy)) in anhydrous dioxane heated to 40° C. was added. 45 805 μl of warm 1,7-bis-(triethoxysilyl)-4,4-bis(ω-methyl-(ethyleneoxy) 45 -methyl) heptane solution. After a total of 48 hours, the solution was cooled to ambient temperature.

[0466] The resulting nanostructure solutions from two identical batches were combined and diluted with water to 50 ml and filtered through a 0.2 μm polyethersulfone (PES) syringe filter. The resulting solution was diluted with water to 800 ml and concentrated to about 20 ml using a tangential flow filtration device with a 300 kD nominal cutoff. The dilution-concentration process was repeated a total of 5 times, and then the solution was further concentrated to 11.3 ml on a rotary filter with a 300 kD nominal cutoff. Average diameter = 35.3 nm, [P] (ICP-OES) = 28 mM.

[0467] A 4 ml sample of the resulting nanostructure solution (112 μmol P) was treated with 228 μl 19.7 mM LuCl3 solution (4.5 μmol Lu) and heated to 60°C for 1 hour, followed by the addition of 1.269 ml 1 M Tris buffer (pH=7.47). After a further 2 hours at 60°C, the solution was filtered through a 0.2 μm PES syringe filter.

[0468] A 3.47 ml sample of the resulting nanostructured solution was mixed with 3.80 ml saline solution and 140 μl 99 mM CaCl2 solution, and then the pH was adjusted to 7.2 with 12 μl 1 M NaOH solution. The solution was diluted to a total volume of 7.5 ml with saline and then filtered through a 0.2 μm PES syringe filter.

[0469] Average diameter (DLS) = 36.0 nm, [P] (ICP-OES) = 9.9 mM, [Si] (ICP-OES) = 46 mM, [Lu] (ICP-OES) = 0.39 mM.

[0470] Test items A and B

[0471] Test items A and B were prepared in a similar manner starting from 37 mM and 65 mM solutions of 1,7-bis(triethoxysilyl)-4,4-bis(dimethylphosphonate) in heptane, respectively.

[0472] Test item A: average diameter (DLS) = 21.3 nm, [P] (ICP-OES) = 8.9 mM, [Si] (ICP-OES) = 48 mM, [Lu] (ICP-OES) = 0.39 mM.

[0473] Test item B: average diameter (DLS) = 27.7 nm, [P] (ICP-OES) = 8.7 mM, [Si] (ICP-OES) = 41 mM, [Lu] (ICP-OES) = 0.39 mM.

[0474] Biodistribution

[0475] The tissue distribution of the test items after intravenous injection in tumor-bearing mice was studied. The injected test items were analyzed for lutetium, silicon, and phosphorus content by ICP-OES. The lutetium value obtained represents the total amount of lutetium injected (i.e., 100%). Each test item was injected intravenously at a concentration of 2μmolLu / kg and 5ml / kg, respectively. Animals for each test item were divided into 4 groups (n=5 mice / group) and killed at 6h, 24h, 48h, and 168h after injection. Three animals were not given medication as controls. At the end of the study, blood samples were collected and blood cells were removed to prepare plasma. After the experiment was terminated, organs (liver, tumor, thigh muscle) were collected. The lutetium content (see Table 4) and silicon content (data not shown) of plasma samples and digested tissue samples were analyzed by ICP-OES. Table 4 shows the distribution of lutetium injected at different times after the injection of the test items.

[0476] Table 4. % injected dose (% ID) of Lu after 6h, 24h, 48h and 168h, "NM" = not measured

[0477]

[0478] As shown in Table 4, the coated nanostructures according to the present application have long circulation, i.e. they have long plasma half-life. In addition, it can be seen that a considerable portion of the nanostructures are distributed into the tumor. This confirms the applicability of the nanostructures of the present application for use in pharmaceutical compositions and for imaging and / or treatment of cancer.

[0479] Example 7 - SEC Chromatography and DLS

[0480] The nanostructures of Example 1A, which had an average diameter of 18.2 nm based on DLS measurements, were also analyzed by size exclusion chromatography (SEC). Peak apex and size distribution were determined by comparison to reference proteins or protein complexes of known size.

[0481] Reference protein standards: bovine serum albumin, 66 kDa, thyroglobulin from bovine thyroid (Thyro-bov), 667 kDa, empty cowpea mosaic virus (CPMV) VLPs, 4360 kDa.

[0482] Figure 6 The chromatogram shows that the nanostructure (bold line) presents a bell-shaped peak, with the apex of the nanostructure peak located near Thyro-bov (19.4 nm measured by DLS). 95.6% of the nanostructure peak area is located between BSA (6.9 nm measured by DLS) and CPMV (29.1 nm measured by DLS), 1.6% of the nanostructure peak area is located above CPMV, and 2.8% of the peak area is located below BSA. The 2.8% portion is mainly the residue of the starting monomer.

[0483] Example 8 - NMR of short-boiled and long-boiled nanostructures

[0484] NMR spectra were recorded at 25 °C on a Varian Unity Inova 500 MHz spectrometer equipped with a Z-spec DBG500-5EF 5 mm dual broadband gradient probe.

[0485] The excitation pulse width was 5.7 μs (corresponding to a 45° inversion angle), the acquisition time was 1.0 s, the repetition delay was 5.0 s, and 4 transients were acquired with a spectral width of i) 200 kHz, 400 k data points or ii) 12 kHz, 24 k data points. The solvent hydrogen signal was gradient shimmed. Recording 31 P NMR spectrum, pulse width 4.9μs, acquisition time 0.02s, repetition delay 1.0s, spectrum width 506kHz, acquisition of 64 transients, 2k data points. Spectra recorded with and without proton decoupling.

[0486] Nanostructure samples synthesized similarly to Examples 1C ("by short boil") and 1B ("by long boil") were transferred into D2O and analyzed by NMR.

[0487] Nanostructures after short and long boiling 1 H NMR Figure 3 The nanostructures subjected to long boiling gave a rather broad spectrum, indicating a higher degree of cross-linking.

[0488] Nanostructures after short and long boiling 31 P NMR spectrum Figure 4 The long boiled sample exhibited a single peak, indicating the presence of only one type of phosphonate, presumably the fully hydrolyzed phosphonate, whereas the short boiled sample exhibited a more complex shape, indicating partial hydrolysis.

[0489] Example 9 - Synthesis of Nanostructures with Low Purity 1,7-Bis(triethoxysilyl)-4,4-Bis(dimethylphosphonate)heptane - Reference Method Not Scope of This Application

[0490] 720 mg of 80% pure unpurified 1,7-bis(triethoxysilyl)-4,4-bis(dimethylphosphonate)heptane and 14.7 ml of 80% (vol / vol) ethylene glycol aqueous solution were placed in a 25 ml 3-neck round-bottom flask, the middle neck of which was equipped with a reflux condenser connected to a vacuum nitrogen manifold and sealed with a glass stopper. The solution was degassed and then heated to gentle reflux in an oil bath. After 44 hours of reflux, the diameter of the nanostructures obtained was 16.2 nm with high dispersion (Dd=2.14).

[0491] Another reaction set up in the same manner, using the same batch of unpurified 1,7-bis(triethoxysilyl)-4,4-bis(dimethylphosphonate)heptane, yielded nanostructures with a diameter of 86.6 nm and high dispersity (Dd=1.95) after 45 hours of reflux.

[0492] This confirms that impure 1,7-bis(triethoxysilyl)-4,4-bis(dimethylphosphonate)heptane is not suitable for the synthesis of nanostructures according to the present application.

[0493] Example 10 - AFM image showing the spherical shape of the nanostructures according to the present application

[0494] Atomic force microscopy (AFM) analysis was performed on the nanostructures prepared according to Example 1B having an average particle size of 19.1 nm.

[0495] AFM Model: Rapid Scan Asyst

[0496] Tip: SSS-NCHR-10 (2nm), spring constant is 10-100N / m

[0497] Imaging mode: Tapping mode using peak force feedback gain instead of cantilever amplitude

[0498] The silicon wafer was cleaned by ultrasonication in acetone for 2 minutes and then blown dry with N2 gas. Ultrasonication was performed again in 2-propanol for 2 minutes and then the wafer was blown dry again with N2 gas. The nanostructures were diluted to a phosphorus concentration of 16 μM in 10 mM aqueous ammonium bicarbonate [(NH4)HCO3] and then a 10 μl droplet was deposited on the cleaned silicon wafer. The droplet on the wafer was dried on a 40°C hot plate for 10 minutes and the nanostructures were analyzed by atomic force microscopy (AFM).

[0499] The results are as follows Figure 7 As shown, a single nanostructure can be seen satisfying the definition of a spherical shape.

[0500] Example 11 - Modeling of Nanostructure Composition by Elemental Analysis

[0501] The nanostructures of Example 1A were dried by freeze drying and then further dried overnight at 120°C before combustion elemental analysis. The results were: C: 24.17%, H: 5.37%, Si: 15.42%, P: 14.81%. Modeling was performed in Excel as follows: The suspected molecular components were added to their relative molar contributions. The major component 1,7-bis(triethoxysilyl)-4,4-bis(dimethylphosphonate)heptane was set to 1 and the molecular weight was set to a hypothetical fully cross-linked, fully hydrolyzed form with a molecular weight of 362 g / mol. Water was then added to formally break the crosslinks since Si-O-Si + H2O → SiOH + HOSi. We know from NMR that there is about 4% by weight of ethylene glycol in the structure and this was also added. The elemental contribution of each molecular component was then calculated and the percentage of each element was calculated and compared to the experimental value. The scores were adjusted to minimize the penalty function for the deviation (the sum of the absolute differences between the modeled and calculated values). In this case, only the water and ethylene glycol contents could be optimized. The best fit to the combustion data was a molar ratio of 1,7-bis(triethoxysilane)-4,4-bis(dimethylphosphonate)heptane, ethylene glycol, and water of 1:0.39:0.01, corresponding to 5.9 bonds between the monomers. This indicates that the nanostructures have the expected composition, with a very high number of bonds between the monomers.

[0502] Example 12 - Determination of Density of Nanostructured Powders

[0503] The freeze-dried nanostructures according to Example 1A were suspended in a series of mixtures of heptane and dibromomethane with different densities. The suspension was centrifuged at 13000 RPM for 5 minutes and the nanostructures were observed to see if they precipitated, floated or suspended. If the density was higher than the heptane-dibromomethane mixture, the particles precipitated; if the density was lower than the heptane-dibromomethane mixture, the particles floated; if the density was similar to the heptane-dibromomethane mixture, the particles suspended. The nanostructures precipitated in the heptane-dibromomethane mixture with a density of 1.561 g / mL and floated in the solvent mixture with a density of 1.736 g / mL. Therefore, the average of these two densities, 1.649, was estimated to be the density of the nanostructures. The high density indicates that the phosphonate has been completely hydrolyzed because bisphosphonic acid has a higher density than the corresponding ester.

[0504] Example 13 - 1,7-bis(triethoxysilyl)-4,4-bis(ω-methyl-(ethyleneoxy) 45 Synthesis of -methyl)heptane

[0505]

[0506] Example 13a: Synthesis of 4,4-bis(ω-methyl-(ethyleneoxy) 45 -methyl)-hept-1,6-diene

[0507] Diallylpropylene glycol (22 g, 0.1411 mol) was dissolved in anhydrous toluene (2.61 l) and cooled in an ice bath. When the internal temperature was below 10°C, NaH (23.7 g, 0.593 mol, 60% (w / v) in mineral oil, 4.2 eq) was added in three portions, keeping the temperature below 10°C. The slurry was then stirred at room temperature for 60 minutes and then added to the m-PEG at 0°C under N2. 45 -Ots (1.071kg, 0.9877mmol, 3.5 equivalents) in anhydrous toluene (2.61l) through azeotropic drying solution. The reaction mixture was heated to reflux overnight and stirred under N2. The reaction was monitored by HPLC and when completed, the temperature was reduced to 15 ℃ and quenched by adding H2O (70ml). The pH of the crude reaction mixture was adjusted to between 5 and 7 with 1.0M HCl (100ml). Due to practical reasons, the crude reaction mixture was divided into two equal parts and extracted two parts respectively. Use H2O (7.14l) to dilute each half of the crude mixture. The temperature was raised to 60 ℃ and NaCl (540g) was added. The mixture was then stirred for 45 minutes and extracted 3 times with EtOAc (2.1l). NaCl (200g) was added to the remaining aqueous phase and the mixture was extracted 3 times again with EtOAc (2.1l). The last three extracts had acceptable product purity (by HPLC analysis) and were dried over MgSO, filtered through a double GF / A filter and the solvent evaporated. The resulting residues were combined and dissolved in H O (2.0 l) and the pH was adjusted to 8 with a 0.8 M NaHCO aqueous solution (100 ml). The aqueous phase was extracted 3 times with DCM (500 mL). The organic phase was dried over MgSO, filtered and evaporated to obtain a white residue.

[0508] Subsequently, the extraction process was repeated on the other half of the crude mixture, and the final products of both extractions were combined with another batch of the same size product synthesized in the same manner to obtain 4,4-bis(ω-methyl-(ethyleneoxy) 45 -methyl)-heptane-1,6-diene (758 g, yield 66.36%, purity 96.8% (HPLC-ELSD)).

[0509] 1 H NMR (400MHz, CDCl3) δ 5.80 (m, 2H), 5.03 (m, 4H), 3.70-3.60 (s, 540H), 3.37 (s, 6H), 3.22 (s, 4H), 2.04 (d, 4H).

[0510] Example 13b: Synthesis of 1,7-bis(triethoxysilyl)-4,4-bis(ω-methyl-(ethyleneoxy) 45 -First 4-(2-(4-(2-methyl-1-oxo-2-yl)-heptane

[0511] At 22°C and N2, 4,4-bis(ω-methyl-(ethyleneoxy) 45 To an azeotropically dried solution of 1-methyl)-heptane-1,6-diene (714 g, 0.172 mol) in toluene (5.5 1) was added triethoxysilane (1117 g, 6.88 mol, 40 equiv). Karstedt's catalyst (25.34 ml, 2% (w / w) in xylene, 1.14 mmol, 0.0066 equiv) was added using a syringe in 1 ml portions over 30 minutes, causing an exotherm of ≤ 2°C. The reaction mixture was stirred at 22°C under N2 overnight.

[0512] pass 1 The disappearance of olefin protons in the reaction was monitored by H-NMR. Thereafter the solvent was evaporated and the excess silane was removed by coevaporation four times with anhydrous toluene (2.5 l). The residue was redissolved in toluene (4.2 l), degassed with 3 vacuum / nitrogen cycles and stirred at 60°C with activated SIR-200 resin (175 g) for 3 days. The solution was filtered from the resin and the resin was washed with toluene (3×2.8 l). The collected fractions were filtered through a double GF / A filter, combined and the solvent evaporated to give 1,7-bis(triethoxysilyl)-4,4-bis(ω-methyl-(ethyleneoxy)) in quantitative yield as a white solid. 45 -methyl)-heptane (783.2 g, ≥99%, purity 94.4% (HPLC-ELSD)).

[0513] 1 H NMR (400MHz, C6D6) δ3.71 (q, 2H), 3.70-3.40 (s, 400H), 3.52 (s, 4H), 3.35 (s, 6H), 1.68 (m, 4H), 1.59 (m, 4H), 1.23 (t, 18H), 0.79 (t, 4H).

[0514] Example 14 - Hydrodynamic Diameter Dispersity of Many Nanostructured Samples, Comparison with the polydispersity index (PDI)

[0515] Nanostructured samples with different dispersities were analyzed by DLS and the dispersity of each sample was calculated. and polydispersity index (PDI) (as shown in Table 5).

[0516] Table 5. Dispersion of many nanostructured samples and polydispersity index (PDI)

[0517]

[0518] From Table 5, we can see that and PDI are related, and both parameters describe the width of the size distribution of the nanostructure population. However, there is no simple monotonic transformation between the two that can fit the data and lead to the conclusion that and PDI capture different aspects of the shape of the size distribution.

Claims

1. A plurality of spherical nanostructures, wherein the plurality of spherical nanostructures has a dispersity between 1 and 1.8; and wherein the nanostructures have a volume average hydrodynamic diameter of 13 nm to 90 nm; wherein each nanostructure comprises a polymer framework of monomer residues, wherein the average number of bonds from each monomer residue is in the range of 3.0 to, but not including, 6.0; wherein the linkages between the monomer residues are Si-O-Si; wherein each nanostructure comprises 10 wt% to 25 wt% silicon; wherein at least 90% of the monomer residues have 5 to 11 carbon atoms; wherein at least 90% of the monomer residues comprise two geminal chelating groups, each chelating group being independently a group according to formula (I), -PO(OR 1 )(OR 2 ) (I) in R 1 and R 2 are independently selected from the group consisting of a negative charge and H; and "-" indicates an internal bond among monomer residues; and wherein the chelating groups according to formula (I) constitute at least 90% of the chelating groups in the nanostructure. 2 . The plurality of spherical nanostructures according to claim 1 , wherein the dispersity is between 1 and 1.5, such as between 1 and 1.3, such as 1.1 to 1.35, such as less than 1.

3.

3. A plurality of spherical nanostructures according to claim 1 or 2, wherein at least 90% of the monomer residues are residues according to formula (II): {(OR 1 )(OR 2 )PO}2-(C){(CH2) n Si(OR 3 )3}{(CH2) n Si(OR 3 )3} (II) in Each R 1 and R 2 independently selected from the group consisting of a negative charge and H; Each R 3 are independently selected from the group consisting of a negative charge, H, and a covalent bond to a polymer framework; wherein at least 3 R 3 is a bond to the polymer framework; and n is an integer between 1 and 5.

4. The plurality of spherical nanostructures according to claim 3, wherein at least four R 3 The - group is a bond to the polymer framework. 5 . The plurality of spherical nanostructures according to claim 3 , wherein n=3.

6. A plurality of spherical nanostructures according to any one of the preceding claims, wherein the nanostructures further comprise a coating, preferably wherein the coating comprises hydrophilic groups.

7. A pharmaceutical composition comprising a plurality of spherical nanostructures according to claim 6.

8. A pharmaceutical composition for use in cancer treatment and / or imaging, wherein the pharmaceutical composition comprises a plurality of spherical nanostructures according to claim 6, wherein the spherical nanostructures further comprise a radioactive isotope.

9. A method for purifying 1,7-bis(triethoxysilyl)-4,4-bis(dimethoxyphosphonate)heptane, the method comprising the following steps: (a) providing a solution of impure 1,7-bis(triethoxysilyl)-4,4-bis(dimethoxyphosphonate)heptane in a polar aprotic solvent; (b) separating the solution and insoluble matter in step (a); (c) concentrating the solution obtained in step (b) to provide a residue; (d) dissolving the residue obtained in step (c) in a non-polar solvent; (e) separating the solution obtained in step (d) from the insoluble matter; (f) removing water from the solution obtained in step (e); (g) concentrating the solution obtained in step (f) to obtain a second residue; (h) subjecting the residue obtained in step (g) to a short straight-through vacuum distillation; and (i) collecting the straight-through fraction from step (h), comprising purified 1,7-bis(triethoxysilyl)-4,4-bis(dimethoxyphosphonate)heptane.

10. The method according to claim 9, wherein The polar aprotic solvent in step (a) is acetonitrile and the solution in step (a) has a concentration of impure 1,7-bis(triethoxysilyl)-4,4-bis(dimethoxyphosphonate)heptane in the range of 25 g / l to 250 g / l; and / or The non-polar solvent in step (d) is a lower alkane, and the solution in step (d) has a concentration of the residue obtained in step (c) in the range of 25 g / l to 250 g / l; and / or The short-path straight-through vacuum distillation in step (h) is carried out in a temperature range of 150° C. to 190° C. and a pressure range of 0.1 mbar to 1 mbar.

11. Use of 1,7-bis(triethoxysilyl)-4,4-bis(dimethoxyphosphonate)heptane purified by the method according to claim 9 or 10 in preparing a plurality of spherical nanostructures according to any one of claims 1 to 6.

12. A method for preparing a plurality of spherical nanostructures according to any one of claims 1 to 5, comprising the following steps: (a) providing a solution comprising a monomer in a mixture of water and a lower alcohol, wherein the monomer is a monomer according to formula (II): {(OR 1 )(OR 2 )PO}2-(C){(CH2) n Si(OR 3 )3}{(CH2) n Si(OR 3 )3}(II) in Each R 1 and R 2 are independently selected from the group consisting of lower alkyl and aryl; and Each R 3 are independently selected from the group consisting of lower alkyl and aryl; and n is an integer between 1 and 5; and (b) placing the solution of step (a) at a temperature of 110° C. to 160° C. for a period of time such that the growth rate of the nanostructure is significantly lower than the initial growth rate.

13. The method according to claim 12, wherein the solution provided in step (a) is provided by dissolving a monomer having a purity greater than 80% in a mixture of water and a lower alcohol.

14. The method of claim 12 or 13, wherein the monomer in step (a) is 1,7-bis-(triethoxysilyl)-4,4-bis-(dimethoxyphosphonate)heptane, and wherein the monomer concentration is 30 mM to 40 mM, the solvent mixture is 10% water in ethylene glycol, and, in step (b), the temperature is 140°C and the heating time is 45 hours to 50 hours.

15. Use of a plurality of spherical nanostructures according to any one of claims 1 to 5 and / or a product of the method according to any one of claims 12 to 14 as an intermediate in the preparation of a plurality of spherical coated nanostructures.

16. Use of a plurality of spherical nanostructures according to any one of claims 1 to 6 and / or a product of the method according to any one of claims 12 to 14 as an intermediate in the preparation of a pharmaceutical product.

17. Use of the pharmaceutical composition according to claim 7 as a carrier of radioisotopes.